Review

Methylation-Based Therapies for Colorectal Cancer

Klara Cervena 1,2, Anna Siskova 1,2, Tomas Buchler 3, Pavel Vodicka 1,2,4 and Veronika Vymetalkova 1,2,4,*

1 Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14 200 Prague, Czech Republic; klara.cervena@iem.cas.cz (K.C.); anna.siskova@iem.cas.cz (A.S.); pavel.vodicka@iem.cas.cz (P.V.)
2 Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic
3 Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic; tomas.buchler@ftn.cz
4 Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic
* Correspondence: veronika.vymetalkova@iem.cas.cz; Tel.: +420-241-062-699

Received: 1 June 2020; Accepted: 23 June 2020; Published: 24 June 2020

Abstract: Colorectal carcinogenesis (CRC) is caused by the gradual long-term accumulation of both genetic and epigenetic changes. Recently, epigenetic alterations have been included in the classification of the CRC molecular subtype, and this points out their prognostic impact. As epigenetic modifications are reversible, they may represent relevant therapeutic targets. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), regulates gene expression. For many years, the deregulation of DNA methylation has been considered to play a substantial part in CRC etiology and evolution. Despite considerable advances in CRC treatment, patient therapy response persists as limited, and their profit from systemic therapies are often hampered by the introduction of chemoresistance. In addition, inter-individual changes in therapy response in CRC patients can arise from their specific (epi)genetic compositions. In this review article, we summarize the options of CRC treatment based on DNA methylation status for their predictive value. This review also includes the therapy outcomes based on the patient’s methylation status in CRC patients. In addition, the current challenge of research is to develop therapeutic inhibitors of DNMT. Based on the essential role of DNA methylation in CRC development, the application of DNMT inhibitors was recently proposed for the treatment of CRC patients, especially in patients with DNA hypermethylation.

Keywords: colorectal cancer; methylation; DNMT inhibitors; therapy

1. Introduction

Human malignancies develop as a result of the accumulation of genetic and epigenetic changes. It is well known that both alterations can be observed not only in cancer cells but also in nonmalignant cells, even before tumor occurs. In addition, epigenetic changes have been identified as crucial mechanisms that underlie colorectal cancer (CRC) development and progression [1–4].

DNA methylation is the most broadly investigated epigenetic alteration (reviewed in [5]). Except for adenine, cytosine, guanine, and thymine, the human genome comprises an additional base, 5-methyl-cytosine (5-mC). 5-mC can be transformed into thymine spontaneously or by deamination controlled enzymatically. Although the brain contains the highest levels of methylated DNA, it is estimated that 5-mC counts for less than 1% of nucleic acids [6]. This methylated form of cytosine is present almost exclusively in connection with CpG dinucleotides. Around 50% of genes in mammal genomes have short (~1 kb long) CpG-rich regions known as CpG islands (CGIs) spread in DNA
Cells 2020, 9, 1540 2 of 30

and are predominantly associated with transcription start sites and promoters [7]. The majority of the cytosines in the CpG sites are methylated in human somatic cells. However, this number alters between diverse tissues and pathological status and is lower with increased age [8].

2. The Source of Methylation Alterations

DNA methylation seems to be caused by exposure to different natural stimulants and dietary factors [9,10]. First, aging has been shown to correlate with aberrant DNA hypermethylation [11]. Additionally, chronic inflammation has been associated with the induction of aberrant DNA hypermethylation [12–15]. It has been determined that patients with chronic inflammation in their bowels are at increased risk of CRC. Cigarette smoking was noted to induce DNA hypermethylation in vitro, and it has been verified in vivo, where high levels of DNA methylation in nonmalignant tissues from the esophagus of smokers were observed [16]. Another inducer of differences in DNA methylation has been ascribed to estrogen treatment in cultured mammary epithelial cells [17]. Dietary factors may affect one-carbon metabolisms, including B vitamins, which are coenzymes in one-carbon metabolisms (vitamins B2, B6, and B12) and might be considered as the regulators of DNA methylation [18]. DNA hypomethylation has been observed during low folate supply and without vitamin B12 in the diet [19,20].

The connection between DNA methylation and aging has been pointed out in the last few decades of research. DNA methylation is an endogenous source of mutations and thus contributes to mutation burden, causing DNA damage and leading to apoptosis and the aging or death of the organism [21]. Several authors have hypothesized that an epigenetic drift or clock associated with aging exists, and they have suggested that DNA methylation is associated with longevity [22–24]. Moreover, Fraga et al. [25] identified, by examining the differences in DNA methylation profiles of monozygotic twins, that younger twins have identical methylomes, while older twins have remarkably different methylomes.

During the development and progression of CRC, several age-related DNA methylation changes can be observed that affect the mRNA expression of genes associated with the transition from adenoma to CRC. While global hypomethylation is characteristic during aging, among age-dependent hypermethylated genes, many tumor suppressor genes have been reported (reviewed in [22,26]).

DNA methylation also plays an important role in the regulation of inflammatory genes in many diseases, including CRC. Many studies have presented that methylation of distinct genes (such as SOCS3 [27], PRKCDBP [28], CYPIB1 [29], PTX3 [30], FXR [31], and VDR [32]) is associated with inflammatory conditions, dysplasia, and malignant transformations, suggesting that these modifications are involved in inflammatory-induced carcinogenesis [12,33,34].

In colitis-associated CRC samples, the expression of DNMT1 was significantly higher than in sporadic CRC tumors, suggesting an increased level of DNA methylation in inflammatory tissues [35]. In addition, hypermethylation of the ITGA4, TFPI2, and VIM gene promoters was noticed in inflammatory tissues of the colon, which may pose a higher risk to the development of colitis-associated CRC [36].

3. Functions of DNA Methylation

This epigenetic alteration is crucial for retroviral elements silencing, regulation of tissue-specific gene expression, genomic imprinting, and the inactivation of the X chromosome. Even though aberrant DNA methylation correlates with transcription silencing, the basic mechanisms are not necessarily the same as gene promoters, gene bodies, or repeated sequences.

Most of the CGIs remain unmethylated in somatic cells; however, some silenced genes contain methylated promoter CGIs. Those are generally limited to genes with long-lasting stabilization of suppressed status such as imprinted genes, genes located on the inactive X chromosome, and genes expressed only in germ cells.

As stated before, many CGIs are situated in promoters, but CGIs can be located within the gene body and in desserts [37]. The majority of gene bodies lack CpGs; however, they are broadly methylated
and have multiple repetitive and transposable elements. Gene body methylation is generally a feature of transcribed genes [38]. Methylation of the CpG sites within exons is the main purpose of C→T transition mutation origin and is responsible for about 30% of all disease-causing mutations in the germline [39,40]. Exons have been shown to be more methylated than introns, and transitions in the level of methylation appear at the boundaries of exons and introns, which may indicate the importance of methylation in the regulation of splicing [41,42]. The nucleosome position data throughout the genome suggest that exons also evince a higher level of nucleosome occupancy in contrast to introns [43], and DNA methylation is higher in DNA comprising nucleosome than in flanking DNA [44].

Methylation in repeating regions, such as centromeres, is important for chromosomal stability [45] (e.g., chromosomal segregation during mitosis) as it might repress the expression of transposable elements [46].

Methylated CGIs at transcriptional start sites (TSSs) are not able to establish transcription after assembling the DNA into nucleosomes [47–49]. It has been shown that methylation at CGI within the promoter represses gene expression. However, most of the genes have at least two TSSs, which likely to represent alternative promoters, and their methylation hampers the interpretation of experiments studying the expression linked to methylation [50,51]. Nevertheless, the question of whether repressed status or methylation comes first has long been a topic of discussion in this area. Genes with CGI in their promoters, which are already repressed by Polycomb complexes, are more likely to be methylated than other genes in cancer: thus, the repressed state precedes methylation [52–55]. Polycomb proteins repress gene expression by histone modification, especially during development and differentiation [56] and silence tumor suppressor genes [57]. The mechanism of alternative gene silencing by Polycomb complex is through the trimethylation of histone H3, chromatin compaction, and regulation of H2A by monoubiquitylation [58,59].

Therefore, it seems that a suppressed state preceding DNA methylation is understood as a fundamental mechanism. However, the results are still not clear. The evidence regarding the timing of DNA methylation suggests that methylation adds another level of stability to epigenetic states. However, tissue-specific methylation changes exist in “shores” and “shelves” surrounding them [60]. These regions bear information that is very important for mediating the control gene expression [60,61]. For example, CGI shores and shelves show higher variation in different cancers, and this site-specific methylation should be kept in mind during the analyses. Differential methylation is not limited to the CGIs but also applies to CpG regions, like at enhancers [62].

There is also a significant fraction of genes that do not display consistency with the methylation-induced repression of transcription. Recently, Spainhour et al. [63] identified that these discrepancies may have several reasons. The authors observed that methylation at particular CpG sites was correlated with corresponding gene expression in the same direction in all cancer types, either with positive or negative correlation. The authors also hypothesized that the connection between DNA methylation and mRNA expression is tissue-independent. In addition, CpG sites close to each other often experience the same trend of correlation with mRNA expression. Another fact influencing the correlation between DNA methylation and gene expression is the position of the CpG site. In the same study of Spainhour [63], the methylation at the CpG site, right before the TSS, was negatively correlated with gene expression, while the methylation at the CpG site after the transcription end site (TES) was positively correlated with expression. This observation points to the fact that methylation of CpG sites at different locations in the gene body displays distinct functions and regulatory effects.

4. DNA Methylation and DNA Methyltransferases (DNMTs)

DNA methylation is an essential process of regulating gene expression without altering the genetic information and is mediated by DNA methyltransferases (DNMTs) that use S-adenosyl-l-methionine as a source of the methyl group. DNMTs can be categorized according to their function into three groups: most abundant DNMT1, de novo DNMTs (DNMT3A and DNMT3B), and DNMT2 (with methylation activity for tRNA) [64,65]. DNMT1 is responsible for maintaining DNA methylation and catalyzes
the attachment of a methyl group to a CpG dinucleotide on DNA strands during replication [66]. DNMT3A and DNMT3B are essential for de novo methylation of the genome, to keep a cell’s specific methylation profile, and also for methylation of newly integrated retroviral sequences [67,68].

The process of transcriptional repression also requires the so-called “reader” molecules, known as methyl-binding proteins (MBPs) and their corepressors, such as histone deacetylases (HDAC1 and HDAC2), Sin3A, and Mi-2 [69]. The role of MBPs is to bind symmetrically to the methylated CpG to attract different members of the chromatin remodeling complex [70]. MBPs contain several proteins that are involved in chromatin remodeling and can be classified into three families based on the functional domains: MBPs with methyl binding domains (MBDs), MBPs that recognizes the methylated DNA according to the Zinc finger motifs, and MBPs with ability to bind methylated DNA using the Set- and RING-associated (SRA) domain [71].

The opposite action to DNA methylation is the elimination of methyl groups, known as the demethylation process. This process involves multiple mechanisms, such as oxidative demethylation of 5-mC, enzymatic removal of the methyl group, or even the base excision repair of the DNA molecule. The demethylation process is facilitated by ten–eleven translocation proteins (TET), the family of proteins that catalyzes the conversion of 5-mC to 5-hydroxycytosine, and subsequently, to cytosine [72]. To promote DNA demethylation, TET1 attaches to the CpG-rich regions in gene promoters and at transcription start sites (TSS) [73].

DNA methylation regulation is mainly facilitated through DNMT1 [74]. DNMT1 modifications are site-specific and enzyme-dependent [74,75]. DNMT1 is also modified by SUMOylation, a process where small ubiquitin modifying proteins (SUMO) are attached by covalent bonds to DNMT1 [76]. In addition, DNMTs can undergo acetylation, phosphorylation, methylation, or ubiquitination [77–79]. Moreover, polycomb (PcG) proteins can directly bind to DNMTs and thus regulate their activity [80].

DNMTs were also studied for their role in CRC pathogenesis. The overexpression of DNMT3B1 increased the number of colon tumors in APC Min/+ mice and enlarged the average size of colorectal adenomas, while the overexpression of DNMT3A1 displayed no effect. DNMT3B1 but not DNMT3A1 methylated the same genes in tumors and in nonmalignant tissues, suggesting that de novo DNMTs can also trigger the methylation and silencing of specific genes in a nonmalignant cell [81]. Interestingly, the overexpression of DNMT3B was associated with a CIMP-high in CRC [82,83]. DNMTs are rarely mutated in cancers. Kanai et al. [84] noticed that mutational changes in the DNMT1 gene that lead to its inactivation in colon cancer cells resulted in changes in the specific DNA methylation profiles.

5. Alterations of DNA Methylation in the Cancer Genome

Aberrant DNA methylation is a hallmark of almost all cancer types. However, many methylation alterations are cancer-specific and appear early in the cancer genome [85], long before the malignant transition, and enlarge with progression [86]. DNA methylation of the promoter CGIs of tumor suppressor genes was suggested as an alternative mechanism in Knudson’s two-hit theory of tumor suppressor gene inactivation, and alongside the specific methylation profile, has been associated with the outcome of different cancer types [87].

The incidence of germline epigenetic features in connection with cancer development in humans is unique, and its presence has so far been found only in familial cancer syndrome. Chan et al. [88] analyzed germline hypermethylation of the MSH2 gene in a three-generation family with hereditary nonpolyposis colorectal cancer (HNPPCC) without evidence of DNA mismatch repair gene mutations. Despite the potential implications for genetic diagnosis, epigenetic inheritance in humans is an underestimated field, with a rare occurrence of uncovered cases.

Cancer genomes synchronously display global hypomethylation as well as gene-promoter-specific hypermethylation. Therefore, the discovery of hypo- and hypermethylated genes might identify new aspects crucial for cancer initiation and progression. In addition, several changes in DNA methylation have an impact on genes involved in carcinogenesis or drug response and represent a promising
therapeutic target [89]. Despite that hypomethylation and hypermethylation show a close relationship to each other, they contribute separately to the CRC [90–92].

The carcinogenic process also involves the interactions between cancer cells and components of the surrounding microenvironment, consisting of the extracellular matrix, fibroblasts, endothelium, and vasculature-associated pericytes, as well as immune cells and occasional adipose cells [93]. Fibroblasts around cancer cells have been considered cancer-associated fibroblasts (CAFs). They differ phenotypically and functionally from normal fibroblasts (NFs) and provide cancer cells with nutrition and energy and stimulate the proliferation, invasion, and metastasis of cells [94,95]. CAFs achieve their activated phenotype in the tumor microenvironment through interactions with tumor cells or tumor-cell-derived biomolecules. CAFs represent the most numerous populations in the tumor stroma, contributing to carcinogenesis by excreting diverse factors (α-smooth muscle actin (α-SMA), fibroblast activation protein α (FAPα), and fibroblast specific protein-1 (FSP-1)) that regulate intercellular signaling in tumor cells, and mechanically restore cancer tissue [96–99]. The epigenetic programming in CAFs serves as a permanent change that stimulates tumor growth [100]. The restoration of the epigenetically silenced gene expressions in the CAF by 5-azacitidine resulted in reduced tumor progression [101]. In CRC, hypomethylation of chondroitin sulfate proteoglycan only occurs in the CAFs of tumor stroma, rather than in cancer cells [102]. DNA promoter hypomethylation may also exist in CAFs. Matsunoki et al. [103] observed that activation of LINE-1 in CRC is due to its hypomethylated promoter.

6. Methylation-based Etiology in CRC

The role of the CpG island methylator phenotype (CIMP) in CRC was already postulated in 1999 by Toyota et al. [104]. The authors demonstrated that the MLH1 gene was frequently inactivated by promoter methylation in the CIMP-positive group of CRC patients.

The majority of the sporadic microsatellite unstable CRC tumors show a CIMP-positive status, while CIMP is infrequent in microsatellite instable (MSI) HNPCC tumors [105,106]. In addition, around 30–40% of sporadic colon cancers located in the proximal colon exhibit CIMP-positive status compared to 3–12% of tumors located in the distal colon and rectal cancers [107–112]. Thus, CIMP is more common in tumors originating in the proximal colon, independent of the MSI status. The presence of CIMP has been correlated with BRAF mutations (BRAF V600E) in both microsatellite stable and MSI colon cancers [105,109,111,113]. CRCs with chromosomal instability (CIN) and CIMP have been shown to correlate inversely [114,115] and develop in two separate pathways [116].

DNA hypermethylation of several CIMP-associated genes has been observed during the early CRC stages [82]. In addition, promoter DNA hypermethylation was determined in the nonmalignant colon mucosa in the patients that had a predisposition to multiple serrated polyps, which are considered as the precursors of CIMP tumors [117]. Weisenberger et al. [105] reported that DNA hypermethylation of the MLH1 gene associated with CIMP is the main mechanism for the evolution of sporadic MSI CRC. Several authors have indicated that KRAS-mutated colorectal tumors are in a close link with specific DNA methylation profiles [118–122]. Several years ago, CIMP-low (CIMP-L) status was significantly associated with KRAS mutations and the male gender, and it is independent of MSI status [118].

Based on these results, there were debates concerning the CRC subtypes classified due to their DNA methylation status. Many researchers believe that patient stratification based on molecular subtypes can help stratify individual patients for specific treatment.

7. CRC Molecular Subtypes in Therapy Outcome Prediction

CRC is a very heterogeneous disease. Each patient has a unique genetic and epigenetic background, and due to this heterogeneity, mortality and response to treatment vary. Thus, CRC can be categorized based on different molecular characteristics. The assessment of molecular subtypes is necessary for a better understanding of the CRC etiology [123], but also important in selecting proper therapy, predicting patient outcomes, and discovering risk factors associated with a particular subtype [124–126]. Historically, CRC classification was done primarily on clinical and pathological characteristics (like tumor
localization, tumor stage, or degree of differentiation). In the last century, it has become clear that CRC can arise through several molecular pathways. The stratification of CRC is also based on molecular features like CIN, MSI, and CIMP.

One of the first studies focusing on molecular subtypes was that of Jass et al. [123]. The authors proposed five molecular subtypes of CRC, which were based on CIN and CIMP status. The basic stratification is shown in Table 1.

| Characteristics | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|-----------------|--------|--------|--------|--------|--------|
| MSI status      | high   | stable–low | stable–low | stable | high–stable |
| Methylations status | high (MLH1) | high (MLH1) | low (MGMT) | negative | negative |
| Mutations       | BRAF   | BRAF   | KRAS   | APC    | -      |
| Origin          | serrated polyps | serrated polyps | adenomas | adenomas | adenomas |
| % of cases      | 12     | 8      | 20     | 57     | 3      |

One year later, a similar classification based on genetic and epigenetic characteristics was introduced [127]. Except for typical molecular characteristics, this classification also included clinical, histological, and pathological features like localization, degree of differentiation, prediction of prognosis, and gender bias. A high methylation profile was described for two groups. Group 1 commonly shows MLH1 methylation, BRAF mutation, and high MSI, and it is associated with a good prognosis, poor differentiation, elderly females, and proximal colon. Group 3 has similar characteristics, but these tumors are typically MSI-low or -stable, and the specific localization is the right-side colon.

In the study of de Sousa et al. [128], the authors classified 90 CRC patients into three subtypes. Two subtypes were effortlessly split up due to specific characteristics (CCS1 associated with CIN and left-sided, CCS2 associated mainly with MSI and right-sided), whereas the results for the CCS3 subtype were more controversial. For this reason, the authors focused on other molecular and clinical characteristics and described that this subtype is also characterized by promoter methylation of WNT target genes [129]. Patients classified into this subtype showed a worse prognosis—more than 50% of them developed a recurrence. Moreover, CCS3 patients with metastatic CRC were resistant to cetuximab independent of the KRAS mutation [128].

Kaneda and Yagi [120,130] developed “two-panel model” methylation markers for CRC classification. First, the authors suggested clustering CRC into three DNA methylation epigenotypes: low- (LME), intermediate- (IME), and high-methylation (HME) epigenotypes. In addition, methylation markers were classified into two other groups: Group 1 methylated specifically in HME that combines the most reported CIMP-related markers, and Group 2 methylated both HME and IME. With this approach, CRC can be properly classified: the first panel (CACNA1G, LOX, SLC30A10) extracts HME using Group 1 methylated markers and the second panel (ELMO1, FBN2, THBD, HAND1 and SLC30A10 again) divides the remaining IME and LME using Group 2 markers. The HME correlates with MSI-H and BRAF mutations, while IME correlates with KRAS mutations and shows a worse prognosis.

Nevertheless, this epigenotype stratification was further replaced by the CMS1 to CMS4 classification proposed by Guinney et al. [131].

There have been a number of other studies defining a lot more CRC subtypes [132,133]. However, it was necessary to come up with some larger study and to establish a gold standard. It was done in 2015 when Guinney et al. [131] described four molecular CRC subtypes. The authors gathered the world’s largest evaluation of data of about 3443 CRC patients (stages II and III) and found out that 87% of CRC cases can fit into four specific groups. This molecular stratification was named as “consensus molecular subtypes” and established as CMS1 (MSI immune subtype), CMS2 (canonical
subtypes, CMS3 (metabolic subtype), and CMS4 (mesenchymal subtype). The summary of typical characteristics for these subtypes is shown in Figure 1. Briefly, high hypermethylation status is peculiar for CMS1, which is as well characterized by a hypermutated status, high MSI, B RAF mutation, increased expression of genes associated with a diffuse immune infiltrate, and worse prognosis. Intermediate level of gene hypermethylation is also observed in CMS3, for which there is a typical K RAS mutation and elevated multiple metabolic signatures. The prognostic effects of CMS subtypes in metastatic CRC are different from those observed in the early stages of CRC, where patients from CMS1 subtype displayed better relapse-free survival, and those in CMS4 subtype evinced shorter relapse-free survival [131]. However, after the assessment of the survival after relapse, the prognostic effects of CMS subtypes were similar between the early-stage CRC patients and the metastatic cohorts [131].

![Figure 1. Consensus molecular subtypes (CMS) classification as proposed by Guinney et al. [131].](image)

Despite many studies published in this field, the relationship between CIMP and molecular subtypes is still not entirely clear. In the last year, Fennell et al. [122] tried to distinguish molecular subtypes based on methylation as the first criterion and thus distinguished patients into 5 groups based on methylation profiles—high levels (CIMP-H1 and CIMP-H2), intermediate levels (CIMP-L1 and CIMP-L2), and low levels (CIMP-negative). It was depicted that CIMP-H1 is strongly correlated with the B RAF mutation, and CIMP-H2 is characteristic of the K RAS mutation. The authors showed that increasing methylation status correlates with increasing age, sex, and tumor location. Moreover, it was shown that methylation has a role in the progression of serrated neoplasia.

The inclusion of patients with distinct CRC molecular subtypes represents an essential start for clinical translation. The prognostic significance of CMS subtypes in both early and metastatic CRCs bolsters the fact that they could be used in the assessment of therapy responses and might aid the treatment choice.

Recently, Kwon et al. [134] demonstrated that molecular classification (CMS1–4) has a predictive value for the prognosis for stage III CRC patients treated with FOLFOX (folinic acid (leucovorin) “FOL”, fluorouracil (5-FU) “F”, and oxaliplatin “OX”) adjuvant chemotherapy. Del Rio et al. reported that the CMS4 subtype was enriched in FOLFIRI (folinic acid (leucovorin) “FOL”, 5-FU “F”, and irinotecan “IRI”) responders by the analysis of 143 CRCs [135]. In another study by Mooi et al. [136], CMS2 and possibly CMS3 tumors benefited from the addition of bevacizumab to first-line capecitabine-based chemotherapy, compared with other CMS groups. The mechanisms responsible for the interaction of CMS groups
with bevacizumab treatment are not yet clear. However, it is remarkable that CMS2 and CMS3 tumors, which responded to bevacizumab, have similar characteristics of highly proliferative epithelial tumors, different from CMS1 and CMS4 that display high immune and stromal infiltration [137]. Okita et al. [138] showed that irinotecan-based therapy is highly effective for CMS4 patients.

CMS analyses in two other metastatic CRC trial cohorts, Cancer and Leukemia Group B (CALGB) 80405 and FIRE-3, have been recently reported [139,140]. In these randomized trials, patients with nonmutated KRAS tumors treated with cetuximab or bevacizumab in combination with first-line chemotherapy for metastatic CRC were studied. Lenz et al. [140] observed that CMS1 subtype patients treated with bevacizumab had a significantly longer overall survival (OS) in contrast to those treated with cetuximab, and CMS2 patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab. These best results were achieved in the subset of CMS1 patients with MSI-H tumors, while the CMS2 group was enriched for left-sided tumors that also responded well to cetuximab therapy in another study [141]. The authors also suggested that oxaliplatin, in combination with bevacizumab, may induce synergistic effects, resulting in marked clinical benefit for patients with CMS1 subtype tumors [128,139,140,142]. In contrast, Stintzing et al. [139] reported better OS after FOLFIRI plus cetuximab therapy versus FOLFIRI plus bevacizumab for CMS3 and CMS4 subtype CRC patients in the FIRE-3 study. Aderka et al. [143] hypothesized that the discrepancies monitored between these two trials, CALGB80405 and FIRE-3, can be due to the trial-specific sequence of chemotherapy plus targeted therapy. However, a recent study of Buchler et al. [144] showed no differences in OS between cohorts treated with first-line bevacizumab and second-line EGFRi (cetuximab or panitumumab) vs. the reverse sequence. Another difference between the data presented by the CALGB80405 and FIRE-3 groups was observed for CMS1 and MSI tumors. In the CALGB80405 study, the CMS1 subtype benefited from the bevacizumab treatment, while cetuximab-treated patients displayed worse outcomes [140]. The poor efficacy of cetuximab in the CMS1 subtype tumors was also noticed in the adjuvant PETACC8 trial. In this trial, patients with CMS1 subtype after the FOLFOX plus cetuximab therapy displayed shorter disease-free survival in comparison to FOLFOX administered alone [145]. This is in agreement that for patients with CMS1 subtype tumors, where oxaliplatin-based therapy combined with cetuximab may actually produce a harmful effect. Concerning the left-sided KRAS wild-type tumors that should be treated with an anti-EGFR agent in first-line treatment according to international guidelines [146,147], the longer OS induced by cetuximab treatment was predominantly evident in CMS3 and CMS4 subtypes in the FIRE-3 study. In the same study, FOLFIRI treatment with either cetuximab or bevacizumab in the CMS2 grouping had no predictive impact.

In short, the CRC classification by CMS subtypes could serve as a significant prognostic biomarker. However, from the clinical point of view, CMS does not seem to have superior value to routinely used clinical indication criteria for selecting patients for optimal treatment with either anti-EGFR or anti-VEGF agents. Overall, the CMS categorization provides a detailed insight into CRC etiology but currently still has no real impact on clinical decision-making.

8. Clinical Applications of DNA Methylation Profiling

Despite the recent progress in the identification of new cancer therapeutics, patients’ response rates to systemic therapy still remain low. The determination of prognostic and predictive biomarkers based on the DNA methylation profiles that can predict patient outcomes and therapeutic responses of advanced CRCs represents an important goal in CRC research. Here, we describe studies investigating the potential utility of methylated genes as predictive biomarkers.

The majority of CRCs (around 80%) evolve through the chromosomal instability pathway (CIN), whereas 10–15% are derived from the microsatellite instability (MSI) pathway that arises as a consequence of a deficient (d) DNA mismatch repair (MMR) system.

Over the last decade, extensive CRC research has suggested several molecular biomarkers, both of prognostic and predictive value. Although plenty of biomarkers have been extensively analyzed, very few of them were confirmed to be valid for the management of CRC, including defects in DNA
mismatch repair (MSI phenotype) and *KRAS* and *BRAF* mutations. All CRC patients should be regularly tested for MMR and MSI status. Patients with CRCs greatly benefit from MSI testing as around 15% of them have deficient MMR tumors (dMMRs), while only 3–5% can be found in mCRCs.

In detail, patients with CRC stages II and III and dMMR after 5-FU based adjuvant therapy were associated with significantly lower tumor recurrence rates and improved survival rates compared with patients with proficient MMR cancers [148]. Overall, in patients with CRC stage II and dMMR, several studies have shown an insufficient benefit of 5-FU-based adjuvant chemotherapy. In patients with stage III disease, the predictive effect of MMR status for adjuvant chemotherapy still remains controversial [149].

Evrard et al. [150] observed that hypermutated dMMR/MSI mCRCs evince higher sensitivity to inhibitors of an immune checkpoint that stimulate cytotoxic T-cells to eliminate dMMR/MSI tumor cells. Additionally, Le et al. [151] concluded that patients with dMMR/MSI tumors greatly benefit from immunotherapy, regardless of the tumor type, with disease control rates of 80% and OS superior to three years in chemoresistant mCRC. On the other hand, the mCRC dMMR/MSI phenotype has been associated with worse prognosis and chemoresistance to standard treatment [150,152]. Recent studies have reported prolonged OS in dMMR/MSI mCRC after antivascular endothelial growth factor (anti-VEGF) treatment as compared to anti-EGFR treatment but without a change in survival conferred to chemotherapy regimen [152]. Finally, recent nonrandomized trials have pointed to the high efficacy of immune checkpoint inhibitors in dMMR/MSI chemoresistant mCRC as a reason for the high tumor mutational burden.

The most studied epigenetically suppressed gene, with an undeniable impact on CRC etiology, is the *hMLH1* hypermethylation. *hMLH1* encodes proteins involved in DNA mismatch repair (MMR), a system that works in a coordinated way to correct DNA mismatches in humans [5,153]. Several years ago, it was noticed that promoter *hMLH1* hypermethylation is associated with a mutator phenotype in sporadic MSI CRCs [154]. The determination of MSI in CRC patients is crucial for their clinical administration. MSI status is routinely assessed by immunostaining of MLH1 and/or by polymerase chain reaction (PCR) amplification of microsatellite sequences that are very stable among humans [155]. CRC patients with MSI display a better prognosis than MSS patients [156]. On the other hand, MSI patients are resistant to 5-FU therapy while being sensitive to oxaliplatin [157]. The study of Jover et al. [158] focused on the determination of CIMP status using the methylation status of five genes: *CACNAG1*, *SOCS1*, *RUNX3*, *NEUROG1*, and *MLH1*. CIMP-negative patients that received adjuvant 5-FU chemotherapy had significantly longer disease-free survival (DFS).

The immunogenic potential of MSI colorectal tumors has resulted in the development of immunotherapeutic approaches [159–162]. Immunomodulatory monoclonal antibodies, such as nivolumab and pembrolizumab, block programmed cell death protein 1 (PD-1), a negative regulator of T-cell activity, and thus enhance the anti-tumor response of T-cells [163]. Recently, it was observed that MMR status profited from therapy based on immune checkpoint blockade with pembrolizumab [151] and with nivolumab [164] in metastatic carcinomas. The positive effect of pembrolizumab was not restricted to MSI CRC and was also observed in metastatic carcinomas with MSI in various tissues of origin [151]. Based on these results, the food and drug administration (FDA) recently approved the use of pembrolizumab and nivolumab as a therapy choice for metastatic solid MSI tumors.

*MGMT* is a gene-encoding O\(^6\)-methylguanine-DNA methyltransferase that repairs mutagenic adduct O\(^6\)-methylguanine, formed by DNA alkylating agents. If these lesions are unrepaired, mutations (GC:AT transitions) arise during DNA replication. Epigenetic silencing of the *MGMT* gene has been associated with G > A mutations in *KRAS* and *TP53* genes [165]. Hypermethylation of *MGMT* has also been observed in adenomas and in the nonmalignant colonic mucosa of CRC patients, and it predicts worse prognosis in different carcinomas, but not in CRC. On the other hand, *MGMT* hypermethylation has been associated with better therapy response using alkylating agents [166,167]. In the study of Nagasaka et al. [168], the methylation status of the *MGMT* gene in tumor tissue from 116 CRC patients receiving adjuvant 5-FU based chemotherapy was determined. The *MGMT* hypermethylation was
associated with better prognosis—patients had a lower chance of experiencing a recurrence after 5-FU based therapy. In addition, the promoter MGMT hypermethylation in plasma of CRC patients has been associated with better response to neoadjuvant therapy [169].

The prediction of therapy response based on the methylation status of LINE-1 gene has also been indicated. In 155 CRC patients (stages II and III) treated with adjuvant 5-FU chemotherapy, LINE-1 hypomethylation was associated with better survival [170]. However, the study of Kaneko et al. [171] described that patients with hypomethylated LINE-1 showed a significantly worse response to FOLFOX-based chemotherapy compared to patients with hypermethylation of this gene. These result discrepancies could be partially explained by the composition of patients’ cohorts, as the study of Kaneko et al. [171] included stage IV patients.

Better response to treatment associated with gene hypermethylation was identified in the study of Jiang et al. [172], where the methylation status of the WNT5A gene was analyzed. The methylation level was significantly higher in patients that respond to 5-FU-based therapy. The vast majority of genes that are found to be hypermethylated are associated with a worse response to therapy. CRC patients with hypermethylated NKX6.1, TFAP2E, IGFBP3, and HYAL2 genes did not profit from 5-FU-based chemotherapy [173–176].

A study focusing on irinotecan-based therapy, as described by Shimizu et al. [177], showed significantly shorter OS and chemoresistance for CRC patients with a methylated BNIP3 gene. Hypermethylation of the CDKN2A gene (encoding protein p16) was associated with a worse response for CRC patients after FOLFOX chemotherapy [178,179]. Patients with no methylated RASSF1A gene had a better response to oxaliplatin-based therapy than patients with aberrant methylation [180].

Aberrant changes in DNA methylation are very promising as these tumor-derived changes might also be monitored in body fluids or stool specimens. Global hypo- and hypermethylation can also be assessed in circulating cell-free DNA isolated from the plasma of CRC patients, thus revealing a novel and low-invasive diagnostic biomarker that is also relevant for early-stage [181].

In summary, several predictive markers based on the DNA methylation profile have been published so far. However, none of these markers have been used in clinics. Studies focusing on the hypermethylation of the MGMT gene showed similar correlations with a good response to 5-FU-based therapy in CRC patients [168,169]. However, more recent, larger, and nonrandomized studies are still needed to confirm these outcomes. For stages II and III CRC patients with 5-FU-based adjuvant chemotherapy, Perez-Carbonell et al. [175] observed that IGFBP3 hypomethylation was associated with longer overall survival and disease-free survival. However, survival was not affected in patients with IGFBP3 hypermethylation.

The CIMP phenotype has also been studied for its predictive value but with conflicting results. CRC patients with negative or low CIMP and with 5-FU- or oxaliplatin-based chemotherapy displayed better prognosis, while patients with positive or high CIMP was associated with better outcomes after chemotherapy in another study [158,182]. Additionally, no association between CIMP status and CRC chemotherapy has been monitored in other studies [178,183].

One of the most studied methylated genes in CRC in body fluids is SEPT9. Septins are GTP-binding proteins that play a role in the regulation of cell cycle and cytokinesis [184]. In a liquid biopsy approach, many studies have proven that SEPT9 can distinguish CRC patients from healthy controls and thus suggested its potential to use this gene as a diagnostic biomarker [185–187]. Other studies have also shown its prognostic potential [188]. Unfortunately, there have not been many studies focusing on therapy response prediction. In the study of Bhangu et al. [189], the methylation status of SEPT9, DCC, BOLL, and SFRP2 genes was established in repeated plasma samples from 34 patients with CRC liver metastasis that had undergone neoadjuvant chemotherapy. The authors observed the dynamic changes in methylated SEPT9 and DCC genes during neoadjuvant chemotherapy. Good responders to neoadjuvant therapy methylation levels decreased during the first 2 cycles.

Monitoring of the plasma levels of mSEPT9 in patients with CRC during treatment seems to be very promising, as the methylated SEPT9 gene has been implicated as a biomarker for colorectal cancer.
Currently, one clinical trial (NCT03334890) is already ongoing to assess the performance of mSEPT9 in assessing the surgical therapeutic effect of CRC.

The studies analyzing the methylation profile as a predictive biomarker, described in this paragraph and others not mentioned above, are summarized in Table 2.

Besides, many CRC prognostic markers based on the DNA methylation status have been published in the literature so far. To date, none of these markers have been used in clinical practice. Recently Draht et al. [190] and Ma et al. [191] comprehensively reviewed the published prognostic methylation markers for CRC and marked the most promising ones. Studies focusing on the hypermethylation of the IGFBP3 gene have shown correlations with a poor prognosis in CRC patients [175,192,193].

The CDKN2A hypermethylation was also associated with poor prognosis in CRC patients [182,194–197]. Interestingly, conflicting results for association with patient survival were observed for MLH1 promoter hypermethylation [198–202]. Many authors have hypothesized that the analysis of all CRC patients as an entity might obscure the real potential of identified biomarkers.
### Table 2. Summary of studies focusing on the predictive potential of methylation profile.

| Origin of the Study | Source | Number of Patients | Gene               | Method          | Treatment Relevance                                                                 | Reference |
|---------------------|--------|--------------------|--------------------|-----------------|-------------------------------------------------------------------------------------|-----------|
| Japan tissue        | 116    | MGMT               | MS-PCR             | hypermethylation predicts good response to 5-FU-based chemotherapy | [168]     |
| Japan tissue        | 155    | LINE-1             | MS-PCR             | hypomethylation predicts good response to 5-FU chemotherapy          | [170]     |
| Japan tissue        | 112    | BNIP3              | qPCR               | presence of methylation is associated with worse response to IRI based chemotherapy | [177]     |
| Spain tissue        | 302    | CACNAG1, SOCS1, RINN3, NEUROG1, MLH1 | pyrosequencing | patients with CIMP+ status do not benefit from 5-FU chemotherapy | [158]     |
| Germany tissue      | 74     | TFAP2E             | qPCR               | hypermethylation is associated with worse response to 5-FU chemotherapy | [174]     |
| Korea tissue        | 322    | NEUROG1, CDKN2A    | Methylight         | concurrent hypermethylation of both genes is associated with recurrence after adjuvant FOLFOX | [178]     |
| USA tissue          | 425    | IGFB3              | bisulfite pyrosequencing | hypermethylation predicts worse response to 5-FU chemotherapy | [175]     |
| China plasma        | 34     | MGMT               | MS-PCR             | hypermethylation is associated with a better response to chemoradiotherapy based on capecitabine and OX | [169]     |
| Germany tissue      | 232    | HYAL2              | MALDI-TOF mass spectrometry | hypermethylation predicts worse response to 5-FU chemotherapy | [176]     |
| Japan tissue        | 40     | LINE-1             | Methylight         | hypomethylation predicts bad response to FOLFOX                         | [171]     |
| Korea tissue        | 49     | CDKN2A             | pyrosequencing     | hypermethylation predicts worse response to chemotherapy based on 5-FU and IRI | [179]     |
| China tissue        | 126    | WNT5A              | MS-PCR             | hypermethylation is associated with better response to 5-FU chemotherapy | [172]     |
| China tissue        | 108 CRC 78 HC | RASSF1A           | MS-PCR             | presence of methylation is associated with better response to OX based chemotherapy | [180]     |
| Austria plasma      | 34     | SEPT9, DCC         | qPCR               | tool for early response assessment in patients receiving neoadjuvant chemotherapy | [189]     |
| China tissue        | 151    | NKX6.1             | MS-PCR             | presence of methylation is associated with worse response to 5-FU chemotherapy | [173]     |
| Korea tissue        | 102    | CHFR               | MS-PCR             | Hypermethylation is associated with good response to chemotherapy based on IRI | [203]     |

5-FU: 5-fluorouracil, IRI: irinotecan, CIMP: CpG island methylator phenotype, OX: oxaliplatin, FOLFOX: folinic acid + fluorouracil + oxaliplatin, MS-PCR: methylation-specific PCR, qPCR: quantitative PCR.
9. DNA Methyltransferase Inhibitors

The DNA methyltransferases (DNMTs), an enzyme that specifically catalyzed DNA methylation, have an important role in the regulation of gene expression, with implications in many diseases, including cancer. The recent research goals lay in the development of therapeutic DNMT inhibitors [204,205]. Inhibitors of DNMT can be divided according to their mechanism of action into two groups: nucleoside analogs that incorporate into DNA, and non-nucleoside inhibitors that interact directly with DNMTs. Both actions lead to the formation of a covalent complex with DNMTs.

Several global DNMT inhibitors, i.e., inhibitors targeting all the DNMTs, have been used in CRC therapy within clinical trials.

9.1. Azacitidine

Azacitidine (5-AZA; Figure 2A), a chemical analog of pyrimidine nucleoside of cytidine, differs by the presence of nitrogen at position 5 of the pyrimidine ring. This molecule was first characterized as a DNMT inhibitor. As a chemotherapeutic agent used in the treatment of cancer, especially for myelodysplastic syndrome and acute myeloid leukemia, it was approved by the FDA in 2004 and by the European Medicines Agency (EMA) in 2002. In clinical use, it is known under the name Vizada [206].

Once 5-AZA is transported into the mammalian cell, 5-AZA is subsequently phosphorylated three times by the serial action of uridine-cytidine kinase and then ribonucleotide reductase to its activated form, azacitidine triphosphate [207,208]. The mechanism of 5-AZA cytotoxicity is through the incorporation into RNA, causing the inhibition of protein synthesis and incorporation into DNA, leading to DNMT depletion. This also supports normal cell growth and cell differentiation by demethylation and the re-expression of tumor suppressor genes [205].

9.2. Decitabine

Decitabine (5-aza-2′-deoxycytidine, DAC; Figure 2B) was discovered together with 5-AZA. DAC is also one of the analogs of cytidine and is very similar to 5-AZA. However, it incorporates only into DNA due to a deoxyribonucleoside (2′-deoxy-5-azacytidine) core. DACs have been reported to be more specific and less toxic than 5-AZA, but both are useful inhibitors of DNA methylation even at low concentrations [209,210]. The knowledge of DAC and 5-AZA cytotoxic effects has strong clinical implications, as these drugs cause DNA damage and protein synthesis disruption at higher concentrations [211,212].

As a drug, it is known under the name Dacogen and was approved by the FDA in 2006 and, in the same year, also by the EMA. The application of DAC is the same as with 5-AZA for myelodysplastic syndrome and acute myeloid leukemia [213]. Nevertheless, 5-AZA has demonstrated better improvement of OS than decitabine [214].

9.3. Guadecitabine

Guadecitabine (SGI-110, S110; Figure 2C) is a unique hypomethylating prodrug of the second generation. SGI-110 is a dinucleotide consisting of DAC connected through a phosphodiester bond to deoxyguanosine that provides protection from cytidine deaminases and, thus, has a prolonged plasma half-life. SGI-110 was designed with better pharmacokinetics and metabolic properties as a replacement for hypomethylating agents such as 5-AZA and DAC [215]. Its lower toxicity and better biological stability were determined in comparison to DAC in vivo in tumor-free nude mice [215].

9.4. Temozolomide

Temozolomide (TMZ; Figure 2D) is an oral prodrug developed in the 1980s in Great Britain [216]. Thanks to its small size (194 Da), it is well absorbed in the small intestine and penetrates easily through the blood–brain barrier. Tumor or nonmalignant cells can be resistant to TMZ via high levels of MGMT, which repairs the O⁶-methylguanine (O⁶-meG) by transferring the methyl group from the O⁶-meG
to its own cysteine residue. Nevertheless, the cytotoxicity of TMZ could be enhanced by promoter hypermethylation of the MGMT gene [217].

TMZ was approved by the FDA in 1999 for the treatment of patients with primary brain tumors [217] and in 2005 for the concomitant treatment of patients with newly diagnosed glioblastoma with radiotherapy. In clinical use, TMZ is known under the name Temodar [218]. In 2010, Temodar’s generic version, named Teva, was also approved by EMA.

Figure 2. (A) Azacitidine, (B) decitabine, (C) guadecitabine, (D) temozolomide.

10. Methylation-Based Therapies

DNMT inhibitors have been studied as the treatment of CRC patients, especially those with evidence of higher levels of DNA methylation.

Demethylation drugs AZA and DAC are synthetic cytosine analogs, which have already been approved for the treatment of acute myeloid leukemia and myelodysplastic syndrome [5,219]. Inhibition of DNMTs by DAC and 5-AZA depends on the DNA replication, as both AZA and DAC can be incorporated into DNA to form covalent bonds with DNMTs and therefore block the DNMT methylation activity. Preclinical studies have shown that DNMT inhibition by AZA or DAC induces apoptosis and reduces the growth of CRC cells. The cytotoxic effect of DAC and AZA has been demonstrated in vitro as well as in xenograft models [220].

In Table 3, seventeen ongoing or completed clinical trials exploring the effect of AZA, DAC, SGI-110, or TMZ in the treatment of CRC patients are listed. These trials are focused on early phases (I and II), with the aim of identifying the outcomes of the utilization of these drugs as single-agent therapy or in combination with immunotherapy or cytotoxic chemotherapy. Of these, eight have been completed, two have been terminated (NCT01882660 due to slow recruitment and NCT00423150 due to low response rate), and the rest are still ongoing or recruiting. However, most of these studies did not show a clear connection between the level of induced demethylation and clinical response, although in most cases, the drugs were well tolerated.

Most of the trials were limited by the exclusion of initial patient stratification according to their methylation profile. The stratification of patients that would benefit from the recurring expression of the already repressed genes by DNMT inhibitors could be promoted by the identification of driver or passenger methylation issues [5]. Special attention is focused on methylation in tumors with epigenetic silencing of hMLH1 (involving in most of the CIMP-high CRCs). When the mutator phenotype is released, numerous mutations might accumulate in MSI-target cancer genes, which largely influence the tumor phenotype [221]. Mutations in the cancer driver genes cannot be repaired by this hMLH1 re-expression; nevertheless, this process could be helpful for increasing the sensitivity to cytotoxic chemotherapy [222].
**Table 3.** Clinical trials on hypo- and hypermethylating chemotherapeutic drugs used in colorectal cancer treatment.

| Clinical Trial | Status/Durance | Origin of Study | Condition | Number of Patients | Drug | Reference |
|----------------|----------------|-----------------|-----------|--------------------|------|-----------|
| NCT01105377    | Completed/2010–2014 | US | Recurrent CC, Recurrent RC, Stage IV CC, Stage IV RC | 47 | Azacitidine | [223] |
| NCT02959437    | Completed/2017–2020 | US, UK, Spain | Solid Tumors, Advanced Malignancies, Metastatic Cancer | 70 | Azacitidine | - |
| NCT01193517    | Completed/2010–2016 | US | CRC | 26 | Azacitidine, Azacitidine MTD | - |
| NCT02260440    | Completed/2015–2017 | US | mCRC | 31 | Azacitidine | [224] |
| NCT02811497    | Active, not recruiting/2016–2022 | Canada | MSS CRC, Platinum-Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor-Positive and HER2-Negative Breast Cancer | 28 | Azacitidine | - |
| NCT02316028    | Completed/2014–2017 | Belgium | Liver Metastasis, CRC | 11 | Decitabine | [225] |
| NCT00879385    | Completed/2009–2013 | US | CRC (wild-type KRAS mCRC) | 21 | Decitabine | [226] |
| NCT01896856    | Completed/2013–2019 | US, Netherlands | Previously Treated mCRC | 96 | SGI-110 (Guadecitabine) | [227] |
| NCT01966289    | Active, not recruiting/2013–2020 | US | mCRC | 18 | SGI-110 (Guadecitabine) | - |
| NCT03576963    | Recruiting/2020–2023 | US | CRC CIMP, MSS mCRC, Refractory CC, CRC Stage IVA, Stage IVB, and Stage IVC | 45 | Guadecitabine | - |
| NCT03519412    | Recruiting/2019–2022 | Italy | CRC, MSI | 348 | Temozolomide | - |
Table 3. Cont.

| Clinical Trial     | Status/Duration     | Origin of Study | Condition                        | Number of Patients | Drug       | Reference |
|--------------------|---------------------|-----------------|----------------------------------|--------------------|------------|-----------|
| NCT01051596        | Completed/2009–2013  | US              | CRC                             | 75                 | Temozolomide | [228]     |
| NCT03832621        | Recruiting/2019–2022| Italy           | mCRC                            | 100                | Temozolomide | -         |
| NCT04166435        | Active, not recruiting/2020–2022 | US | CRC | 30 | Temozolomide | -         |
| NCT02414009        | Unknown/2014–2017   | Italy           | mCRC                            | 82                 | Temozolomide | [229], [230] |
| NCT01882660        | Terminated/2013–2018| Netherland      | CC                              | 88                 | Decitabine | -         |
| NCT00423150        | Terminated/2007–2017| UK              | CRC, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm | 86 | Temozolomide | [231]     |

CRC: colorectal cancer, mCRC: metastatic CRC, CC: colon cancer, RC: rectal cancer, CIMP: CpG island methylator phenotype, MSI: microsatellite instability, MSS: microsatellite stable.
11. Conclusions

Despite current progress in the improvement and invention of drugs with anticancer activity, the current systemic therapy for CRC is far from optimum due to limited efficacy in the unselected patient population. This highlights the necessity to identify new biomarkers that can determine the patient’s response to a specific treatment.

The study of DNA methylation is in the foreground, and it has been shown that methylation status can predict patients’ response to treatment. In detail, methylation of MGMT and IGFB3 genes and CIMP status are considered for their predictive value in 5-FU based-chemotherapies. DNA methylation markers may thus improve treatment strategy and could even be used for screening in the future. In addition, DNA methylation biomarkers may facilitate the development of precision medicine.

The main problem with the use of global and specific DNMT inhibitors is their excessive demethylating effect that leads to the reactivation of tumor suppressor genes as well as oncogenes. A new approach should lie in the development of such DNMT inhibitors that might target the specific interaction, utilizing DNMT targets and leading thus to antitumorigenic phenotypes with no modification of oncogenes by methylation (i.e., oncogene inhibition). Currently obtained results exploiting this concept are encouraging.

In addition, the combination of methylation-based therapies with standard chemotherapeutic drugs shows both additive and synergistic effects. However, many epigenetic modification-targeting drugs such as demethylating agents 5-AZA and DAC are inherently and highly toxic. Another problem with DAC and 5-AZA is their rapid elimination in plasma; this problem circumvented by the development of their derivatives for longer half-life, such as SGI-110.

Several global projects have been developed to facilitate our understanding of how genetic and epigenetic mechanisms regulate gene expression, such as the Encyclopedia of DNA Elements (ENCODE, 2003), The Cancer Genome Atlas (TCGA, 2006), and International Cancer Genome Consortium (ICGC, 2008), the Consortium for Epigenomics Mapping of the National Institutes of Health (2008), and the European Community Initiative BLUEPRINT (2011). Using next-generation sequencing approaches, these programs have helped to identify epigenomic differences between healthy and pathological states. Epigenomic profiling has significantly improved our understanding of complex human diseases, such as cancer. The International Consortium for Human Epigenome (IHEC, 2010) [232] was established to develop reference maps of at least 1000 epigenomes for health- and disease-related cell states [233] and to publish data to boost clinical applications.

Considerable efforts are currently being made to identify biomarkers associated with therapy response and thus discriminate against patients who will benefit from chemotherapy. The identification of these biomarkers is crucial for individualized treatment strategies in all CRC patients. The identification of these biomarkers might stratify patients into groups with specific treatment and promote the shift from a universal approach to precision medicine. These biomarkers should be able to distinguish responders from nonresponders with relative ease and low cost and to be non-invasive to increase screening acceptability. DNA methylation markers can improve treatment strategy in the future and facilitate the development of precision medicine. We believe that these changes can be tracked non-invasively in ctDNA released into plasma during the administration of chemotherapy. The sequential methylation mapping in serial blood specimens might contribute to the improvement of therapeutic strategies in CRC.

Author Contributions: Conceptualization K.C., A.S., T.B., and V.V.; writing—review and editing K.C., A.S., T.B., P.V., and V.V.; writing—original draft preparation K.C., A.S., T.B., and V.V.; data curation and investigation K.C., A.S., T.B., and V.V.; funding acquisition K.C. and V.V.; project administration K.C., A.S., T.B., P.V., and V.V.; supervision T.B., P.V., and V.V. All authors have read and agreed to the published version of the manuscript.

Funding: This project was supported by the Grant Agency of the Ministry of Health of the Czech Republic (AZV 17–30920A and NV19–09–00237), the Charles University Research Centre program UNCE/MED/006 “University Center of Clinical and Experimental Liver Surgery” provided by the Ministry of Education Youth and Sports of the Czech Republic, and the Grant Agency of Charles University (GAUK 302119).
Conflicts of Interest: TB received honoraria from Roche, Bristol Myers Squibb, Merck Sharp Dohme, and Servier (unrelated to the present article). Other authors declare that there are no conflicts of interest.

Abbreviations

- 5-AZA: azacytidine
- 5-FU: 5-fluorouracil
- 5-mC: 5-methyl-cytosine
- CALGB: Cancer and Leukemia Group B
- CC: colon cancer
- CGIs: CpG islands
- CIMP: CpG island methylator phenotype
- CIMP-L: CpG island methylator phenotype low
- CIN: chromosomal instability
- CMS: colorectal molecular subtype
- CRC: colorectal cancer
- DAC: decitabine
- DFS: disease-free survival
- DNMT: DNA methyltransferases
- EMA: European Medicines Agency
- FDA: Food and drug administration
- FOL: folinic acid
- HNPCC: hereditary nonpolyposis colorectal cancer
- IRI: irinotecan
- mCRC: metastatic CRC
- MMR: DNA mismatch repair
- MSI: microsatellite instability
- MS-PCR: Methylation-specific PCR
- MSS: microsatellite stable
- O6-meG: O6-methylguanine
- OS: overall survival
- OX: oxaliplatin
- PCR: polymerase chain reaction
- PD-1: programmed cell death protein 1
- qPCR: quantitative PCR
- RC: rectal cancer
- SGI-110: guadecitabine
- TMZ: temozolomide
- TSS: transcriptional start sites

References

1. Lazennec, G.; Lam, P.Y. Recent discoveries concerning the tumor-mesenchymal stem cell interactions. *Biochim. Biophys. Acta Rev. Cancer* **2016**, *1866*, 290–299. [CrossRef] [PubMed]
2. El Bairi, K.; Tariq, K.; Himri, I.; Jaafari, A.; Smaili, W.; Kandhro, A.H.; Gouri, A.; Ghazi, B. Decoding colorectal cancer epigenomics. *Cancer Genet.* **2018**, *220*, 49–76. [CrossRef] [PubMed]
3. Farkas, S.; Vymetalkova, V.; Vodickova, L.; Vodicka, P.; Nilsson, T.K. DNA methylation changes in genes frequently mutated in sporadic colorectal cancer and in the DNA repair and Wnt/β-catenin signaling pathway genes. *Epigenomics* **2014**, *6*, 179–191. [CrossRef] [PubMed]
4. Vymetalkova, V.; Vodicka, P.; Pardini, B.; Rosa, F.; Levy, M.; Schneiderova, M.; Liska, V.; Vodickova, L.; Nilsson, T.K.; Farkas, S. Epigenome-wide analysis of DNA methylation reveals a rectal cancer-specific epigenomic signature. *Epigenomics* **2016**, *8*, 1193–1207. [CrossRef]
5. Vymetalkova, V.; Vodicka, P.; Vodenkova, S.; Alonso, S.; Schneider-Stock, R. DNA methylation and chromatin modifiers in colorectal cancer. *Mol. Asp. Med.* **2019**, *69*, 73–92. [CrossRef]
6. Ehrlich, M.; Gama-Sosa, M.A.; Huang, L.-H.; Midgett, R.M.; Kuo, K.C.; McCune, R.A.; Gehrke, C. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. *Nucleic Acids Res.* 1982, 10, 2709–2721. [CrossRef]

7. Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. *Nat. Rev. Genet.* 2012, 13, 484–492. [CrossRef]

8. Fraga, M.F.; Esteller, M. Epigenetics and aging: The targets and the marks. *Trends Genet.* 2007, 23, 413–418. [CrossRef]

9. Takeshima, H.; Ushijima, T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. *NPJ Precis. Oncol.* 2019, 3. [CrossRef] [PubMed]

10. Mathers, J.C.; Strathdee, G.; Relton, C.L. Induction of Epigenetic Alterations by Dietary and Other Environmental Factors. *Adv. Genet.* 2010, 71, 3–39. [CrossRef] [PubMed]

11. Issa, J.-P.; Ottaviano, Y.L.; Celano, P.; Hamilton, S.R.; Davidson, N.E.; Baylin, S.B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat. Genet.* 1994, 7, 536–540. [CrossRef] [PubMed]

12. Issa, J.-P.; Ahuja, N.; Toyota, M.; Bronner, M.P.; A Brentnall, T. Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res.* 2001, 61, 3573–3577. [PubMed]

13. Niwa, T.; Tsukamoto, T.; Toyoda, T.; Mori, A.; Tanaka, H.; Maekita, T.; Ichinose, M.; Tatematsu, M.; Ushijima, T. Inflammatory Processes Triggered by Helicobacter pylori Infection Cause Aberrant DNA Methylation in Gastric Epithelial Cells. *Cancer Res.* 2010, 70, 1430–1440. [CrossRef] [PubMed]

14. Nishida, N.; Nagasaka, T.; Nishimura, T.; Ikai, I.; Boland, C.R.; Goel, A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. *Hepatology* 2008, 47, 908–918. [CrossRef] [PubMed]

15. Gonzalez-Jaramillo, V.; Portilla-Fernandez, E.; Glisic, M.; Voortman, T.; Ghanbari, M.; Bramer, W.; Chowdhury, R.; Nijsten, T.; Dehghan, A.; Franco, O.H.; et al. Epigenetics and Inflammatory Markers: A Systematic Review of the Current Evidence. *Int. J. Inflamm.* 2019, 2019, 6273680. [CrossRef] [PubMed]

16. Oka, D.; Yamashita, S.; Tomioka, T.; Nakanishi, Y.; Kato, H.; Kaminishi, M.; Ushijima, T. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history. *Cancer* 2009, 115, 3412–3426. [CrossRef]

17. Cheng, A.; Culhane, A.C.; Chan, M.W.Y.; Venkataramu, C.R.; Ehrich, M.; Nasir, A.; Rodriguez, B.A.; Liu, J.; Yan, P.S.; Quackenbush, J.; et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. *Cancer Res.* 2008, 68, 1786–1796. [CrossRef]

18. Choi, S.-W.; Corrocher, R.; Friso, S. Nutrients and DNA methylation. In *Nutrition and Epigenetics*, 1st ed.; CRC Press: Boca Raton, FL, USA, 2009; pp. 106–125.

19. Reed, M.C.; Nijhout, H.F.; Neuhouser, M.L.; Gregory, J.F.; Shane, B.; James, S.J.; Boynton, A.; Ulrich, C.M. A Mathematical Model Gives Insights into Nutritional and Genetic Aspects of Folate-Mediated One-Carbon Metabolism. *J. Nutr.* 2006, 136, 2653–2661. [CrossRef]

20. Kadaiyfi, F.Z.; Zheng, S.; Pan, Y.-X. Molecular Mechanisms Underlying the Link between Diet and DNA Methylation. *Int. J. Mol. Sci.* 2018, 19, 4055. [CrossRef]

21. Mazin, A.L. Suicidal function of DNA methylation in age-related genome disintegration. *Ageing Res. Rev.* 2009, 8, 314–327. [CrossRef]

22. Johnson, A.A.; Akman, K.; Calimport, S.; Wuttke, D.; Stolzting, A.; De Magalhães, J.P. The Role of DNA Methylation in Aging, Rejuvenation, and Age-Related Disease. *Rejuvenation Res.* 2012, 15, 483–494. [CrossRef] [PubMed]

23. Jones, M.J.; Goodman, S.J.; Kobor, M.S. DNA methylation and healthy human aging. *Aging Cell* 2015, 14, 924–932. [CrossRef] [PubMed]

24. Horvath, S.; Zhang, Y.; Langfelder, P.; Kahn, R.S.; Boks, M.P.M.; Van Eijk, K.; Berg, L.H.V.D.; Ophoff, R.A. Aging effects on DNA methylation modules in human brain and blood tissue. *Genome Biol.* 2012, 13, R97. [CrossRef] [PubMed]

25. Fraga, M.F.; Ballestar, E.; Paz, M.F.; Ropero, S.; Setien, F.; Ballestar, M.L.; Heine-Suñer, D.; Cigudosa, J.C.; Urioste, M.; Benitez, J.; et al. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc. Natl. Acad. Sci. USA* 2005, 102, 10604–10609. [CrossRef]

26. Jung, M.; Pfeifer, G.P. Aging and DNA methylation. *BMC Biol.* 2015, 13, 7. [CrossRef]
27. Li, Y.; Deuring, J.; Peppelenbosch, M.P.; Kuipers, E.J.; De Haar, C.; Van Der Woude, C.J. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. *Carcinogenesis* 2012, 33, 1889–1896. [CrossRef]

28. Lee, J.-H.; Kang, M.-J.; Han, H.-Y.; Lee, M.-G.; Jeong, S.-I.; Ryu, B.-K.; Ha, T.-K.; Her, N.-G.; Han, J.; Park, S.J.; et al. Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNF-Induced Apoptosis. *Clin. Cancer Res.* 2011, 17, 7551–7562. [CrossRef]

29. Patel, S.A.A.; Bhambra, U.; Charalambous, M.P.; David, R.M.; Edwards, R.J.; Lightfoot, T.; Boobis, A.R.; Gooderham, N.J. Interleukin-6-mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. *Br. J. Cancer* 2014, 111, 2287–2296. [CrossRef]

30. Rubino, M.; Kunderfranco, P.; Basso, G.; Greco, C.M.; Pasqualini, F.; Serio, S.; Roncalli, M.; Laghi, L.; Mantovani, A.; Papait, R.; et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. *Oncoimmunology* 2017, 6, e1333215. [CrossRef] [PubMed]

31. I Selmin, O.; Fang, C.; Lyon, A.M.; Doetschman, T.C.; A Thompson, P.; Martinez, J.D.; Smith, J.W.; Lance, P.M.; Romagnolo, D.F. Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells. *J. Nutr.* 2015, 146, 236–242. [CrossRef]

32. Castellano-Castillo, D.; Morcillo, S.; Clemente-Postigo, M.; Cruijeras, A.B.; Fernández-García, J.C.; Torres, E.; Tinahones, F.J.; Macias-González, M. Adipose tissue inflammation and VDR expression and methylation in colorectal cancer. *Clin. Epigenetics* 2018, 10, 60. [CrossRef] [PubMed]

33. Yang, Z.-H.; Dang, Y.-Q.; Ji, G. Role of epigenetics in transformation of inflammation into colorectal cancer. *World J. Gastroenterol.* 2019, 25, 2863–2877. [CrossRef] [PubMed]

34. West, N.; McCuaig, S.; Franchini, F.; Powrie, F.M. Emerging cytokine networks in colorectal cancer. *Nat. Rev. Immunol.* 2015, 15, 615–629. [CrossRef] [PubMed]

35. Foran, E.; Garrity-Park, M.M.; Mureau, C.; Newell, J.; Smyrk, T.C.; Limburg, P.J.; Egan, L.J. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. *Mol. Cancer Res.* 2010, 8, 471–481. [CrossRef]

36. Gerecke, C.; Scholinka, B.; Löwenstein, V.; Fait, I.; Gottschalk, U.; Rogoll, D.; Melcher, R.; Kleuser, B. Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: Putative risk markers for colitis-associated cancer. *J. Cancer Res. Clin. Oncol.* 2015, 141, 2097–2107. [CrossRef]

37. A Jones, P. The DNA methylation paradox. *Trends Genet.* 1999, 15, 34–37. [CrossRef]

38. Vaiserman, A.M. *Epigenetics of Aging and Longevity*, 1st ed.; Academic Press: London, UK, 2017.

39. Rideout, W.; Coetzee, G.; Olumi, A.; Jones, P. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. *Science* 1990, 249, 1288–1290. [CrossRef]

40. Cooper, D.N.; Youssoufiyan, H. The CpG dinucleotide and human genetic disease. *Qual. Life Res.* 1988, 78, 151–155. [CrossRef]

41. Laurent, L; Wong, E.; Li, G.; Huynh, T.; Tsirigos, A.; Ong, C.T.; Low, H.M.; Sung, W.-K.; Rigoutsos, I.; Loring, J.F.; et al. Dynamic changes in the human methylome during differentiation. *Genome Res.* 2010, 20, 320–331. [CrossRef]

42. Maunakea, A.K.; Chepelev, I.; Cui, K.; Zhao, K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. *Cell Res.* 2013, 23, 1256–1269. [CrossRef]

43. Schwartz, S.; Mesheror, E.; Ast, G. Chromatin organization marks exon-intron structure. *Nat. Struct. Mol. Biol.* 2009, 16, 990–995. [CrossRef] [PubMed]

44. Chodavarapu, R.K.; Feng, S.; Bernatavichute, Y.V.; Chen, P.-Y.; Stroud, H.; Yu, Y.; Hetzel, J.A.; Kuo, F.; Kim, J.; Cokus, S.J.; et al. Relationship between nucleosome positioning and DNA methylation. *Nature* 2010, 466, 388–392. [CrossRef] [PubMed]

45. Moarefi, A.H.; Chédin, F. ICF Syndrome Mutations Cause a Broad Spectrum of Biochemical Defects in DNMT3B-Mediated De Novo DNA Methylation. *J. Mol. Biol.* 2011, 409, 758–772. [CrossRef]

46. Scelfo, A.; Fachinetti, D. Keeping the Centromere under Control: A Promising Role for DNA Methylation. *Cells* 2019, 8, 912. [CrossRef] [PubMed]

47. Hashishony, T.; Zhang, J.; Kesheit, I.; Bustin, M.; Cedar, H. The role of DNA methylation in setting up chromatin structure during development. *Nat. Genet.* 2003, 34, 187–192. [CrossRef] [PubMed]

48. Kass, S.U.; Landsberger, N.; Wolfe, A.P. DNA methylation directs a time-dependent repression of transcription initiation. *Curr. Biol.* 1997, 7, 157–165. [CrossRef]
49. Venolia, L.; Gartler, S.M. Comparison of transformation efficiency of human active and inactive X-chromosomal DNA. *Nature* 1983, 302, 82–83. [CrossRef]

50. Landry, J.-R.; Mager, D.L.; Wilhelm, B.T. Complex controls: The role of alternative promoters in mammalian genomes. *Trends Genet.* 2003, 19, 640–648. [CrossRef]

51. Maunakea, A.K.; Nagarajan, R.P.; Bilenky, M.; Ballinger, T.J.; D’Souza, C.; Fouse, S.D.; Johnson, B.E.; Hong, C.; Nielsen, C.; Zhao, Y.; et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. *Nature* 2010, 466, 253–257. [CrossRef]

52. Gal-Yam, E.N.; Egger, G.; Iniguez, L.; Holster, H.; Einarsson, S.; Zhang, X.; Lin, J.C.; Liang, G.; Jones, P.A.; Tanay, A. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. *Proc. Natl. Acad. Sci. USA* 2008, 105, 12979–12984. [CrossRef]

53. Ohm, J.E.; McGarvey, K.M.; Yu, X.; Cheng, L.; Schuebel, K.E.; Cope, L.; Mohammad, H.P.; Chen, W.; Daniel, V.C.; Yu, W.; et al. A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nat. Genet.* 2007, 39, 157–158. [CrossRef] [PubMed]

54. Schlesinger, Y.; Straussman, R.; Keshet, I.; Farkash, S.; Hecht, M.; Zimmerman, J.; Eden, E.; Yakhini, Z.; Ben-Shushan, E.; Reubinoff, B.; et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. *Nat. Genet.* 2006, 39, 232–236. [CrossRef]

55. Vissers, J.H.A.; Van Lohuizen, M.; Citterio, E. The emerging role of Polycomb repressors in the response to DNA damage. *J. Cell Sci.* 2012, 125, 3939–3948. [CrossRef]

56. Francis, N.J. Chromatin Compaction by a Polycomb Group Protein Complex. *Science* 2004, 306, 1574–1577. [CrossRef]

57. Smith, Z.D.; Meissner, A. DNA methylation: Roles in mammalian development. *Nat. Rev. Genet.* 2013, 14, 204–220. [CrossRef] [PubMed]

58. Cheng, X.; Blumenthal, R. Mammalian DNA Methyltransferases: A Structural Perspective. *Structure* 2008, 16, 341–350. [CrossRef] [PubMed]

59. Zhang, W.; Xu, J. DNA methyltransferases and their roles in tumorigenesis. *Biomark. Res.* 2017, 5, 1. [CrossRef] [PubMed]
69. Nan, X.; Ng, H.H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, R.N.; Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature* **1998**, *393*, 386–389. [CrossRef]

70. Privalsky, M.L. *Transcriptional Corepressors: Mediators of Eukaryotic Gene Repression*; Springer: Heidelberg, Germany, 2013.

71. Mahmood, N.; Rabbani, S.A. DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications. *Front. Oncol.* **2019**, *9*, 489. [CrossRef]

72. Buck-Koehntop, B.A.; Defossez, P.-A. On how mammalian transcription factors recognize methylated DNA. *Epigenetics* **2013**, *8*, 131–137. [CrossRef]

73. Guo, J.U.; Su, Y.; Zhong, C.; Ming, G.-L.; Song, H. Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain. *Cell* **2011**, *145*, 423–434. [CrossRef]

74. Qin, W.; Leonhardt, H.; Pichler, G. Regulation of DNA methyltransferase 1 by interactions and modifications. *Nucleus* **2011**, *2*, 392–402. [CrossRef]

75. Edwards, J.R.; Yarychkivska, O.; Boulard, M.; Bestor, T.H. DNA methylation and DNA methyltransferases. *Epigenetics Chromatin* **2017**, *10*, 23. [CrossRef]

76. Lee, B.; Muller, M.T. SUMOylation enhances DNA methyltransferase 1 activity. *Biochem. J.* **2009**, *421*, 449–461. [CrossRef]

77. Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Kutay, H.; Motiwala, T.; Jacob, S.T. 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal. *Mol. Cell. Biol.* **2005**, *25*, 4727–4741. [CrossRef]

78. Deshaies, R.J. SCF and Cullin/RING H2-Based Ubiquitin Ligases. *Annu. Rev. Cell Dev. Biol.* **1999**, *15*, 435–467. [CrossRef]

79. Naumann, M.; Bech-Otschir, D.; Huang, X.; Ferrell, K.; Dubiel, W. COP9 Signalosome-directed c-Jun Activation/Stabilization Is Independent of JNK. *J. Biol. Chem.* **1999**, *274*, 35297–35300. [CrossRef]

80. Viré, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Mirjolet, C.; Morey, L.; Van Eynde, A.; Bernard, D.; Vanderwinden, J.-M.; et al. The Polycomb group protein EZH2 directly controls DNA methylation. *Nature* **2005**, *439*, 871–874. [CrossRef]

81. Linhart, H.G.; Lin, H.; Yamada, Y.; Steine, E.J.; Gokhale, S.; Lo, G.; Cantu, E.; Ehrlich, M.; He, T.; et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. *Genome Res.* **2007**, *21*, 3110–3122. [CrossRef]

82. Ibrahim, A.E.K.; Arends, M.J.; Silva, A.-L.; Wyllie, A.H.; Greger, L.; Ito, Y.; Vowler, S.L.; Huang, T.-H.-M.; Murrell, A.; Breton, J.D.; et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. *Cell. Biol.* **2010**, *60*, 499–508. [CrossRef]

83. Nosho, K.; Shima, K.; Irahara, N.; Kure, S.; Baba, Y.; Kirkner, G.J.; Shen, L.; Gokhale, S.; Hazra, A.; Spiegelman, N.; et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. *Clin. Cancer Res.* **2009**, *15*, 3663–3671. [CrossRef]

84. Kanai, Y.; Ushijima, S.; Nakano, Y.; Sakamoto, M.; Hirohashi, S. Mutation of the DNA methyltransferase (DNMT1) gene in human colorectal cancers. *Cancer Lett.* **2003**, *192*, 75–82. [CrossRef]

85. Bernal, C.; Vargas, M.; Ossandón, E.; Santibañez, E.; Urrutia, J.; Luengo, V.; Zavala, L.F.; Backhouse, C.; Palma, M.; Aragón, J.; et al. DNA methylation profile in diffuse type gastric cancer: Evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis. *Boil. Res.* **2009**, *41*, 303–315. [CrossRef]

86. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. *Carcinog* **2009**, *31*, 27–36. [CrossRef]

87. Ying, J.; Li, H.; Seng, T.J.; Langford, C.; Srivastava, G.; Tsaio, S.W.; Putti, T.; Murray, P.; Chan, A.; Tao, Q. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. *Oncogene* **2005**, *25*, 1070–1080. [CrossRef]

88. Chan, T.L.; Yuen, S.T.; Kong, C.K.; Chan, Y.W.; Chan, A.S.; Ng, W.F.; Tsui, W.Y.; Lo, M.W.; Tam, W.Y.; Li, V.S.W.; et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. *Nat. Genet.* **2006**, *38*, 1178–1183. [CrossRef]

89. Yang, X.; Lay, E.; Han, H.; Jones, P.A. Targeting DNA methylation for epigenetic therapy. *Trends Pharmacol. Sci.* **2010**, *31*, 536–546. [CrossRef]
90. Bariol, C.; Suter, C.; Cheong, K.; Ku, S.-L.; Meagher, A.; Hawkins, N.; Ward, R. The Relationship between Hypomethylation and CpG Island Methylation in Colorectal Neoplasia. *Am. J. Pathol.* 2003, 162, 1361–1371. [CrossRef]

91. Ehrlich, M. The Controversial Denouement of Vertebrate DNA Methylation Research. *Biochemistry* 2005, 70, 568–575. [CrossRef]

92. Frigola, J.; Sole, X.; Paz, M.F.; Moreno, V.; Esteller, M.; Capellá, G.; Feinado, M.A. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. *Hum. Mol. Genet.* 2004, 14, 319–326. [CrossRef]

93. Plava, J.; Cihova, M.; Burikova, M.; Matuskova, M.; Kucerova, L.; Miklikova, S. Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. *J. Cancer* 2019, 18, 67. [CrossRef]

94. Xing, F. Cancer associated fibroblasts (CAFs) in tumor microenvironment. *Front. Biosci.* 2010, 15, 166. [CrossRef]

95. Du, H.; Che, G. Genetic alterations and epigenetic alterations of cancer-associated fibroblasts. *Oncol. Lett.* 2016, 13, 3–12. [CrossRef]

96. Karagiannis, G.S.; Poutahidis, T.; Erdman, S.E.; Kirsch, R.; Riddell, R.H.; Diamandis, E. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. *J. Cancer Res.* 2012, 10, 1403–1418. [CrossRef]

97. Gascard, P.; Tlsty, T.D. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. *Genome Res.* 2016, 30, 1002–1019. [CrossRef]

98. Ishii, G.; Ochiai, A.; Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. *Adv. Drug Deliv. Rev.* 2016, 99, 186–196. [CrossRef]

99. Son, G.M.; Kwon, M.-S.; Shin, D.-H.; Shin, N.; Ryu, D.; Kang, C.-D. Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer. *BMC Cancer* 2012, 12, 574. [CrossRef]

100. Fiori, M.E.; Di Franco, S.; Villanova, L.; Bianca, P.; Stassi, G.; De Maria, R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. *Mol. Cancer* 2019, 18, 70. [CrossRef]

101. Banerjee, J.; Mishra, R.; Li, X.; Jackson, R.S.; Sharma, A.; Bhowmick, N.A. A reciprocal role of prostate cancer on stromal DNA damage. *Oncogene* 2013, 33, 4924–4931. [CrossRef]

102. Adany, R.; Heimer, R.; Caterson, B.; Sorrell, J.M.; Iozzo, R.V. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. *J. Biol. Chem.* 1990, 265, 11389–11396.

103. Matsunoki, A.; Kawakami, K.; Kotake, M.; Kaneko, M.; Kitamura, H.; Ooi, A.; Watanabe, G.; Minamoto, T. LINE-1 methylation shows little intra-patient heterogeneity in primary and synchronous metastatic colorectal cancer. *BMC Cancer* 2012, 12, 574. [CrossRef]

104. Toyota, M.; Ahuja, N.; Suzuki, H.; Itoh, F.; Imai, K.; Baylin, S.B.; Issa, J.P. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res.* 1999, 59, 5438–5442. [PubMed]

105. Weisenberger, D.J.; Siegmund, K.; Campan, M.; Young, J.; I Long, T.; Faasse, M.; Kang, G.H.; Widschwendter, M.; Weener, D.; et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat. Genet.* 2006, 38, 787–793. [CrossRef] [PubMed]

107. Hawkins, N.; Norrie, M.; Cheong, K.; Mokany, E.; Ku, S.-L.; Meagher, A.; O’Connor, T.; Ward, R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. *Gastroenterology* 2002, 122, 1376–1387. [CrossRef] [PubMed]

108. Van Rijnsoever, M.; Grieu, F.; Elsaleh, H.; Joseph, D.; Iacopetta, B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. *Gut* 2002, 51, 797–802. [CrossRef]

109. Slattery, M.L.; Curtin, K.; Wolff, R.K.; Boucher, K.M.; Sweeney, C.; Edwards, S.; Caan, B.J.; Samowitz, W. A Comparison of Colon and Rectal Somatic DNA Alterations. *Dis. Colon Rectum* 2009, 52, 1304–1311. [CrossRef]
110. Barault, L.; Charon-Barra, C.; Jo oste, V.; De La Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.-M.; Laurent-Puig, P.; Faiyre, J.; et al. Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases. *Cancer Res.* 2008, 68, 8541–8546. [CrossRef]

111. Nosho, K.; Irahara, N.; Shima, K.; Kure, S.; Kirkner, G.J.; Schernhammer, E.; Hazra, A.; Hunter, D.J.; Barault, L.; Charon-Barra, C.; Jooste, V.; De La Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.-M.; Ogino, S.; Goel, A. Molecular Classification and Correlates in Colorectal Cancer. *Gastroenterology* 2005, 129, 837–845. [CrossRef]

112. English, D.R.; Young, J.P.; Simpson, J.A.; Jenkins, M.A.; Southey, M.C.; Southey, M.C.; Anderson, K.E.; Walther, A.; Johnstone, E.; Swanton, C.; Midgley, R.; Tomlinson, I.; Kerr, R.S. Genetic prognostic and predictive markers in colorectal cancer. *Histopathology* 2007, 50, 113–130. [CrossRef]

113. Samowitz, W.S.; Albertsen, H.; Herrick, J.; Levin, T.R.; Sweeney, C.; Murtaugh, M.; Wolff, R.K.; Slattery, M.L. Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer. *Gastroenterology* 2005, 129, 837–845. [CrossRef]

114. Goel, A.; Nagasaka, T.; Arnold, C.N.; Inoue, T.; Hamilton, C.; Niedzwiecki, D.; Compton, C.; Mayer, R.J.; Goldberg, R.; Bertagnolli, M.M.; et al. The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer. *Gastroenterology* 2007, 132, 127–138. [CrossRef] [PubMed]

115. Cheng, Y.-W.; Pincas, H.; Baczolod, M.D.; Schemmann, G.; Giardina, S.F.; Huang, J.; Barral, S.; Idrees, K.; Khan, S.A.; Zeng, Z.; et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. *Clin. Cancer Res.* 2008, 14, 6005–6013. [CrossRef]

116. Leggett, B.; Whitehall, V.L.J. Role of the Serrated Pathway in Colorectal Cancer Pathogenesis. *Gastroenterology* 2010, 138, 2088–2100. [CrossRef] [PubMed]

117. Young, J.; Jass, J.R. The Case for a Genetic Predisposition to Serrated Neoplasia in the Colorectum: Hypothesis and Review of the Literature. *Cancer Epidemiol. Biomark. Prev.* 2006, 15, 1778–1784. [CrossRef] [PubMed]

118. Ogino, S.; Kawasaki, T.; Kirkner, G.J.; Loda, M.; Fuchs, C.S. CpG Island Methylator Phenotype-Low (CIMP-Low) in Colorectal Cancer: Possible Associations with Male Sex and KRAS Mutations. *J. Mol. Diagn.* 2006, 8, 582–588. [CrossRef] [PubMed]

119. Takekne, K.; Akagi, K.; Fukuyo, M.; Yagi, K.; Takayama, T.; Kaneda, A. DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. *Cancer Med.* 2017, 6, 1023–1035. [CrossRef] [PubMed]

120. Yagi, K.; Akagi, K.; Hayashi, H.; Nagaie, G.; Tsujii, S.; Isagawa, T.; Midorikawa, Y.; Sakamoto, H.; Seto, Y.; et al. Three DNA Methylation Epigenotypes in Human Colorectal Cancer. *Clin. Cancer Res.* 2009, 16, 21–33. [CrossRef]

121. Sakai, E.; Ohata, K.; Chiba, H.; Matsuhashi, N.; Doi, N.; Fukushima, J.; Endo, H.; Takahashi, H.; Tsuji, S.; Yagi, K.; et al. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. *Int. J. Cancer* 2014, 135, 1586–1595. [CrossRef]

122. Fennell, L.J.; Dumenil, T.; Wockner, L.; Hartel, G.; Nones, K.; Bond, C.; Borowsky, J.; Liu, C.; McKeone, D.; Bowdler, L.; et al. Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas. *Cell. Mol. Gastroenterol. Hepatol.* 2019, 8, 269–290. [CrossRef]

123. Jass, J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology* 2007, 50, 113–130. [CrossRef]

124. English, D.R.; Young, J.P.; Simpson, J.A.; Jenkins, M.A.; Southey, M.C.; Southey, M.C.; Anderson, K.E.; Walther, A.; Johnstone, E.; Swanton, C.; Midgley, R.; Tomlinson, I.; Kerr, R.S. Genetic prognostic and predictive markers in colorectal cancer. *Nat. Rev. Cancer* 2009, 9, 489–499. [CrossRef] [PubMed]

125. Limsui, D.; Vierkant, R.; Tillmans, L.S.; Wang, A.H.; Weisenberger, D.J.; Laird, P.W.; Lynch, C.F.; Anderson, K.E.; French, A.J.; Haile, R.W.; et al. Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. *J. Natl. Cancer Inst.* 2010, 102, 1012–1022. [CrossRef] [PubMed]

126. Hinoue, T.; Weisenberger, D.J.; Lange, C.P.; Shen, H.; Byun, H.-M.; Berg, D.V.D.; Malik, S.; Pan, F.; Noushmehr, H.; Van Dijk, C.M.; et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res.* 2011, 22, 271–282. [CrossRef] [PubMed]

127. Ogino, S.; Goel, A. Molecular Classification and Correlates in Colorectal Cancer. *J. Mol. Diagn.* 2008, 10, 13–27. [CrossRef]
128. Melo, F.D.S.E.; Wang, X.; Jansen, M.; Fessler, E.; Trinh, A.; De Rooy, L.P.M.H.; De Jong, J.H.; De Boer, O.J.; Van Leersum, R.; Bijlsma, M.F.; et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. *Nat. Med.* 2013, 19, 614–618. [CrossRef]

129. Melo, F.D.S.E.; Colak, S.; Buikhuizen, J.; Koster, J.; Cameron, K.; De Jong, J.H.; Tuynman, J.B.; Prasetyanti, P.R.; Fessler, E.; Bergh, S.P.V.D.; et al. Methylation of Cancer-Stem-Cell-Associated Wnt Target Genes Predicts Poor Prognosis in Colorectal Cancer Patients. *Cell Stem Cell* 2011, 9, 476–485. [CrossRef]

130. Kaneda, A.; Yagi, K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. *Cancer Sci.* 2011, 102, 18–24. [CrossRef]

131. Guinney, J.; Dienstmann, R.; Wang, X.; De Reynies, A.; Schlicher, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. *Nat. Med.* 2015, 21, 1350–1356. [CrossRef]

132. Marisa, L.; De Reynies, A.; Duval, A.; Selves, J.; Gaub, M.P.; Vescovo, L.; Ettiene-Grimaldi, M.-C.; Schiappa, R.; Guenet, D.; Ayadi, M.; et al. Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. *PLoS Med.* 2013, 10, e1001453. [CrossRef]

133. Mooi, J.; Wirapati, P.; Asher, R.; Lee, C.; Savas, P.S.; Price, T.; Townsend, A.; Hardingham, J.E.; Buchanan, D.; Williams, D.; et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer. *J. Pathol.* 2013, 231, 63–76. [CrossRef]

134. Kwon, Y.; Park, M.; Jang, M.; Yun, S.; Kim, W.K.; Kim, S.; Paik, S.; Lee, H.J.; Hong, S.; Kim, T.I.; et al. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. *Oncotarget* 2017, 8, 39367–39381. [CrossRef] [PubMed]

135. Del Rio, M.; Mollevi, C.; Bibeau, F.; Vie, N.; Selves, J.; Emile, J.-F.; Roger, P.; Gongora, C.; Robert, J.; Tubiana-Mathieu, N.; et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. *Eur. J. Cancer* 2017, 76, 68–75. [CrossRef] [PubMed]

136. Mooi, J.; Wirapati, P.; Asher, R.; Lee, C.; Savas, P.S.; Price, T.; Townsend, A.; Hardingham, J.E.; Buchanan, D.; Williams, D.; et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial. *Ann. Oncol.* 2018, 29, 2240–2246. [CrossRef] [PubMed]

137. Dienstmann, R.; Salazar, R.; Tabernero, J. The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning. *Am. Soc. Clin. Oncol. Educ. Book* 2014, 34, 91–99. [CrossRef]

138. Okita, A.; Takahashi, S.; Ouchi, M.; Inoue, M.; Watanabe, M.; Endo, M.; Honda, H.; Yamada, Y.; Ishioka, C. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. *Oncotarget* 2018, 9, 18698–18711. [CrossRef]

139. Stintzing, S.; Wirapati, P.; Lenz, H.-J.; Neureiter, D.; Von Weikersthal, L.F.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Keintges, T.; et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRe plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. *Ann. Oncol.* 2019, 30, 1796–1803. [CrossRef] [PubMed]

140. Lenz, H.-J.; Ou, F.-S.; Venook, A.P.; Hochster, H.S.; Niedzwiecki, D.; Goldberg, R.M.; Mayer, R.J.; Bertagnolli, M.M.; Blanke, C.D.; Zemla, T.; et al. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). *J. Clin. Oncol.* 2019, 37, 1876–1885. [CrossRef]

141. Arnold, D.; Lueza, B.; Douillard, J.-Y.; Peeters, M.; Lenz, H.-J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J.-P.; Tabernero, J.; et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Ann. Oncol.* 2017, 28, 1713–1729. [CrossRef]

142. Trinh, A.; Trumpi, K.; Melo, F.D.S.E.; Wang, X.; De Jong, J.H.; Fessler, E.; Kuppen, P.J.; Reimers, M.S.; Swets, M.; Koopman, M.; et al. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. *Clin. Cancer Res.* 2016, 23, 387–398. [CrossRef]

143. Aderka, D.; Stintzing, S.; Heinemann, V. Explaining the unexplainable: Discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. *Lancet Oncol.* 2019, 20, e274–e283. [CrossRef]

144. Bächler, T.; Chloupkova, R.; Poprach, A.; Fiala, O.; Kiss, I.; Kopecckova, K.; Dusek, L.; Veskrnova, V.; Slavicek, L.; Kohoutek, M.; et al. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: A national registry-based analysis. *Cancer Manag. Res.* 2018, 11, 359–368. [CrossRef]
145. Marisa, L.; Ayadi, M.; Balogou, R.; Pilati, C.; Le Malicot, K.; Lepage, C.; Emile, J.-F.; Salazar, R.; Aust, D.E.; Duval, A.; et al. Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort. *J. Clin. Oncol.* 2017, 35, 3509. [CrossRef]

146. Yoshino, T.; Arnold, D.; Taniguchi, H.; Pentherrudakis, G.; Yamazaki, K.; Xu, R.-H.; Kim, T.; Ismail, F.; Tan, I.; Yeh, K.-H.; et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann. Oncol.* 2018, 29, 44–70. [CrossRef]

147. Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobero, A.; Van Krieken, J.H.J.; Aderka, D.; Aguilar, E.A.; Bardelli, A.; Benson, A.; Bodoky, G.; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann. Oncol.* 2016, 27, 1386–1422. [CrossRef] [PubMed]

148. Sinicrope, F.; Foster, N.R.; Thibodeau, S.N.; Marsoni, S.; Monges, G.; Labianca, R.; Yothers, G.; Allegra, C.; Moore, M.J.; Gallinger, S.; et al. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. *J. Natl. Cancer Inst.* 2011, 103, 863–875. [CrossRef] [PubMed]

149. Bender, U.; Rho, Y.; Barrera, I.; Aghajanyan, S.; Acoba, J.; Kavan, P. Adjuvant therapy for stages II and III colon cancer: Risk stratification, treatment, duration and future directions. *Curr. Oncol.* 2019, 26, S43–S52. [CrossRef] [PubMed]

150. Evrard, C.; Tachon, G.; Randrian, V.; Karayan-Tapon, L.; Tougeron, D.; Tapon, K. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. *Cancers* 2019, 11, 1567. [CrossRef] [PubMed]

151. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N. Engl. J. Med.* 2015, 372, 2509–2520. [CrossRef]

152. Venderbosch, S.; Nagtegaal, I.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M.T.; Richman, S.D.; et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. *Clin. Cancer Res.* 2014, 20, 5322–5330. [CrossRef] [PubMed]

153. Nojadeh, J.N.; Behrouz Sharif, S.; Sakhinia, E. Microsatellite instability in colorectal cancer. *EXCLI J.* 2018, 17, 159–168.

154. Kane, M.F.; Loda, M.; Gaida, G.M.; Lipman, J.; Mishra, G.; Goldman, H.; Jessup, J.M.; Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. *Cancer Res.* 1997, 57, 808–811. [PubMed]

155. Boland, C.R.; Thibodeau, S.N.; Hamilton, S.R.; Sidransky, D.; Eshleman, J.R.; Burt, R.W.; Meltzer, S.J.; A Rodriguez-Bigas, M.; Fodde, R.; Ranzani, G.N.; et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998, 58, 5248–5257. [CrossRef] [PubMed]

156. Peruchó, M. Microsatellite instability: The mutator that mutates the other mutator. *Nat. Med.* 1996, 2, 630–631. [CrossRef] [PubMed]

157. Tougeron, D.; Mouillet, G.; Trouilloud, I.; LeComte, T.; Coriat, R.; Aparicio, T.; Guetz, G.D.; Lécaillle, C.; Artru, P.; Sickersen, G.; et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. *J. Natl. Cancer Inst.* 2016, 108. [CrossRef] [PubMed]

158. Jover, R.; Nguyen, T.; Pérez–Carbonell, L.; Zapater, P.; Payá, A.; Alenda, C.; Rojas, E.; Cubiella, J.; Balagué, F.; Morillas, J.D.; et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. *Gastroenterology* 2010, 140, 1174–1181. [CrossRef]

159. Schwitalla, Y.; Linnebacher, M.; Ripberger, E.; Gebert, J.; Doeberitz, M.V.K. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. *Cancer Immun.* 2004, 4, 14.

160. Linnebacher, M.; Gebert, J.; Rudy, W.; Woerner, S.; Yuan, Y.P.; Bork, P.; Doeberitz, M.V.K.; Yuan, Y. Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. *Int. J. Cancer* 2001, 93, 6–11. [CrossRef]

161. Ishikawa, T.; Fujita, T.; Suzuki, Y.; Okabe, S.; Yuasa, Y.; Iwai, T.; Kawakami, Y. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. *Cancer Res.* 2003, 63, 5564–5572.
162. Saeterdal, I.; Bjerveim, J.; Lislerud, K.; Gjertsen, M.K.; Bukholm, I.K.; Olsen, O.C.; Nesland, J.M.; Eriksen, J.A.; Møller, M.; Lindblom, A.; et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. *Proc. Natl. Acad. Sci. USA* 2001, 98, 13255–13260. [CrossRef]

163. Brunner-Weinzierl, M.C.; Rudd, C.E. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy. *Front. Immunol.* 2018, 9, 2737. [CrossRef]

164. Overman, M.J.; McDermott, R.; Leach, J.L.; Lonardi, S.; Lenz, H.-J.; Morse, M.A.; Desai, J.; Hill, A.; Axelson, M.; Moss, R.A.; et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. *Lancet Oncol.* 2017, 18, 1182–1191. [CrossRef]

165. Esteller, M.; García-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-Repair Gene MGMTand the Clinical Response of Gliomas to Alkylating Agents. *N. Engl. J. Med.* 2000, 343, 1350–1354. [CrossRef] [PubMed]

166. Amatu, A.; Sartore-Bianchi, A.; Moutinho, C.; Belotti, A.; Bencardino, K.; Chirico, G.; Cassingena, A.; Rusconi, F.; Esposito, A.; Michelatti, M.; et al. Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. *Clin. Cancer Res.* 2013, 19, 2265–2272. [CrossRef] [PubMed]

167. Fornaro, L.; Vivaldi, C.; Caparello, C.; Musettini, G.; Baldini, E.; Masi, G.; Falcone, A. Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond. *Front. Biosci.* 2016, 8, 170–180. [CrossRef]

168. Naganaka, T.; Sharp, G.B.; Notohara, K.; Kambara, T.; Sasamoto, H.; Isozaki, H.; Maipchee, D.G.; Jass, J.R.; Tanaka, N.; Matsubara, N. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. *Clin. Cancer Res.* 2003, 9, 5306–5312. [PubMed]

169. Sun, W.; Sun, Y.; Zhu, M.; Wang, Z.; Zhang, H.; Xin, Y.; Jiang, G.; Guo, X.; Zhang, Z.; Liu, Y. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. *Oncol. Rep.* 2013, 31, 1466–1472. [CrossRef] [PubMed]

170. Kawakami, K.; Matsuoki, A.; Kaneko, M.; Saito, K.; Watanabe, G.; Minamoto, T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. *Cancer Sci.* 2010, 102, 166–174. [CrossRef] [PubMed]

171. Kaneko, M.; Kotake, M.; Bando, H.; Yamada, T.; Takemura, H.; Minamoto, T. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. *BMC Cancer* 2016, 16, 945. [CrossRef]

172. Jiang, G.; Lin, J.; Wang, W.; Sun, M.; Chen, K.; Wang, F. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy. *Genet. Test. Mol. Biomark.* 2017, 21, 74–79. [CrossRef]

173. Chang, S.-Y.; Kuo, C.-C.; Wu, C.-C.; Hsiao, C.-W.; Hu, J.-M.; Hsu, C.-H.; Chou, Y.-C.; Shih, Y.-L.; Lin, Y.-W. NXX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy. *Genes Chromosomes Cancer* 2018, 57, 268–277. [CrossRef]

174. Ebert, M.P.; Tänzer, M.; Balluff, B.; Burgermeister, E.; Kretzschmar, A.K.; Hughes, D.J.; Tetzner, R.; Lofton-Day, C.; Rosenberg, R.; Reinauer-Schick, A.; et al. TFAP2E–DKK4 and Chemoresistance in Colorectal Cancer. *Genet. Test. Mol. Biomark.* 2012, 16, 44–53. [CrossRef] [PubMed]

175. Perez-Carbonell, L.; Balaguer, F.; Toiyama, Y.; Egoavil, C.M.; Rojas, E.; Guarinos, C.; Andreu, M.; Llor, X.; Castells, A.; Jover, R.; et al. IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal Cancer. *PLoS ONE* 2014, 9, e104285. [CrossRef] [PubMed]

176. Pfütze, K.; Benner, A.; Hoffmeister, M.; Jansen, L.; Yang, R.; Bläker, H.; Herpel, E.; Ulrich, A.; Ulrich, C.M.; Chang-Claude, J.; et al. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. *Genomics* 2015, 106, 348–354. [CrossRef]

177. Shimizu, S.; Iida, S.; Ishiguro, M.; Utake, H.; Ishikawa, T.; Takagi, Y.; Kobayashi, H.; Higuchi, T.; Enomoto, M.; Mogushi, K.; et al. Methylated BNIP3 gene in colorectal cancer prognosis. *Oncol. Lett.* 2010, 1, 865–872. [CrossRef] [PubMed]

178. Han, S.-W.; Lee, H.-J.; Bae, J.M.; Cho, N.-Y.; Lee, K.-H.; Kim, T.-Y.; Oh, D.-Y.; Im, S.-A.; Bang, Y.-J.; Jeong, S.-Y.; et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. *Int. J. Cancer* 2012, 132, 2209–2216. [CrossRef] [PubMed]
Kim, S.H.; Park, K.H.; Shin, S.J.; Lee, K.Y.; Kim, T.I.; Kim, N.K.; Rha, S.Y.; Roh, J.K.; Ahn, J.B.  
192. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI 
Chemotherapy in Patients with Metastatic Colorectal Cancer. Cancer Res. Treat. 2016, 48, 208–215. [CrossRef]  

Sun, X.; Yuan, W.; Hao, F.; Zhuang, W. Promoter Methylation of RASSF1A indicates Prognosis for Patients 
with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Med. Sci. Monit. 2017, 
23, 5389–5395. [CrossRef]  

Nagai, Y.; Sunami, E.; Yamamoto, Y.; Hata, K.; Okada, S.; Murono, K.; Yasuda, K.; Otani, K.; Nishikawa, T.; 
Tanaka, T.; et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for 
colorectal cancer. Oncotarget 2017, 8, 11906–11916. [CrossRef]  

Cha, Y.; Kim, K.-J.; Han, S.-W.; Rhee, Y.Y.; Bae, J.M.; Wen, X.; Cho, N.-Y.; Lee, D.-W.; Lee, K.-H.; Kim, T.-Y.; 
et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. 
Br. J. Cancer 2016, 115, 164–171. [CrossRef]  

Cohen, S.A.; Wu, C.; Yu, M.; Gourgioti, G.; Wirtz, R.; Raptou, G.; Gkakou, C.; Kotoula, V.; Pentheroudakis, G.; 
Papaxoinis, G.; et al. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer 
Treated With Adjuvant Oxaliplatin. Clin. Color. Cancer 2015, 15, 164–169. [CrossRef]  

Hall, P.A.; Russell, S.H. The pathobiology of the septin gene family. J. Pathol. 2004, 204, 489–505. [CrossRef] 

Lofton-Day, C.; Model, F.; Devos, T.; Tetzner, R.; Distler, J.; Schuster, M.; Song, X.; Lesche, R.; Liebenberg, V.; 
Ebert, M.; et al. DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening. Clin. Chem. 
2008, 54, 414–423. [CrossRef]  

Lee, H.S.; Hwang, S.M.; Kim, T.S.; Kim, D.-W.; Park, D.J.; Kang, S.-B.; Kim, H.-H.; Park, K.U. Circulating 
Methylated Septin 9 Nucleic Acid in the Plasma of Patients with Gastrointestinal Cancer in the Stomach and 
Colon. Transl. Oncol. 2013, 6, 290–IN4. [CrossRef] [PubMed]  

Tham, C.; Chew, M.; Soong, R.; Lim, J.; Ang, M.; Tang, C.; Zhao, Y.; Ong, S.Y.K.; Liu, Y. Postoperative serum 
methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients 
with colorectal cancer. Cancer 2014, 120, 3131–3141. [CrossRef]  

Bhangu, J.S.; Beer, A.; Mittlböck, M.; Tamandl, D.; Walter, P.; Schönthaler, S.; Taghizadeh, H.; Stremitz, S.; 
Kaczirek, K.; Gruenberger, T.; et al. Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal 
Cancer. Clin. Chem. 2009, 55, 1337–1346. [CrossRef] [PubMed]  

Lee, H.S.; Hwang, S.M.; Kim, T.S.; Kim, D.-W.; Park, D.J.; Kang, S.-B.; Kim, H.-H.; Park, K.U. Circulating 
Methylated Septin 9 Nucleic Acid in the Plasma of Patients with Gastrointestinal Cancer in the Stomach and 
Colon. Ann. Surg. 2018, 268, 894–902. [CrossRef]  

Draht, M.X.G.; Goudkade, D.; Koch, A.; Grabsch, H.I.; Weijenberg, M.P.; Van Engeland, M.; Melotte, V.; 
Smits, K. Prognostic DNA methylation markers for sporadic colorectal cancer: A systematic review. 
Clin. Epigenetics 2018, 10, 35. [CrossRef]  

Ma, Z.; Williams, M.; Cheng, Y.Y.; Leung, W.K. Roles of Methylated DNA Biomarkers in Patients with 
Colorectal Cancer. Dis. Markers 2019, 2019, 1–8. [CrossRef]  

Yi, J.M.; Dhir, M.; Van Neste, L.; Downing, S.R.; Jeschke, J.; Glöckner, S.C.; Calmon, M.D.F.; Hooker, C.M.; 
Funes, J.M.; Boshoff, C.; et al. Genomic and epigenomic integration identifies a prognostic signature in colon 
cancer. Clin. Cancer Res. 2011, 17, 1535–1545. [CrossRef]  

Fu, T.; Pappou, E.P.; Guzzetta, A.A.; Calmon, M.D.F.; Sun, L.; Herrera, A.; Li, F.; Wolfgang, C.L.; Baylin, S.B.; 
Iacobuzio-Donahue, C.A.; et al. IGBP3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II 
Colorectal Cancers. Ann. Surg. 2016, 263, 337–344. [CrossRef] [PubMed]  

Esteller, M.; González, S.; Risques, R.A.; Marcello, E.; Mangues, R.; Germà, J.R.; Herman, J.G.; Capellá, G.; 
Peinado, M.A. K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer. J. Clin. Oncol. 
2001, 19, 299–304. [CrossRef]  

Wettergren, Y.; Odin, E.; Nilsson, S.; Carlsson, G.; Gustavsson, B. p16INK4a Gene Promoter Hypermethylation 
in Mucosa as a Prognostic Factor for Patients with Colorectal Cancer. Mol. Med. 2008, 14, 412–421. [CrossRef] 

Kohonen-Corish, M.R.; Teung, J.; Chan, C.; Currey, N.; Dent, O.F.; Clarke, S.; Bokey, L.; Chapuis, P.H. KRAS 
mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict 
recurrence of rectal cancer. Int. J. Cancer 2014, 134, 2820–2828. [CrossRef]
197. Kim, S.H.; Park, K.H.; Shin, S.J.; Lee, K.Y.; Kim, T.I.; Kim, N.K.; Rha, S.Y.; Ahn, J.B. CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. *Yonsei Med. J.* 2018, 59, 588–594. [CrossRef] [PubMed]

198. Miladi-Abdennadher, I.; Abdelmaksoud-Damak, R.; Ayadi, L.; Khabir, A.; Frihka, F.; Kallel, L.; Frihka, M.; Sellami-Boudawara, T.; Gargouri, A.; Mokdad-Gargouri, R. Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. *Biosci. Rep.* 2011, 31, 257–264. [CrossRef] [PubMed]

199. Jensen, L.H.; Rasmussen, A.A.; Byriel, L.; Kuramochi, H.; Krüger, D.G.; Lindelbjerg, J.; Danenberg, P.V.; Jakobsen, A.; Danenberg, K. Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: A descriptive and prognostic cancer marker study. *Cell. Oncol.* 2013, 36, 411–419. [CrossRef] [PubMed]

200. Iida, S.; Kato, S.; Ishiguro, M.; Matsuyama, T.; Ishikawa, T.; Kobayashi, H.; Higuchi, T.; Uetake, H.; Ennomoto, M.; Sugihara, K. PIK3CA mutation and methylation influences the outcome of colorectal cancer. *Oncol. Lett.* 2011, 3, 565–570. [CrossRef] [PubMed]

201. Wang, Z.; Yuan, X.; Jiao, N.; Zhu, H.; Zhang, Y.; Tong, J. CDH13 and FLBN3 Gene Methylation are Associated with Poor Prognosis in Colorectal Cancer. *Pathol. Oncol. Res.* 2011, 18, 263–270. [CrossRef]

202. Kuan, J.C.; Wu, C.C.; Sun, C.A.; Chu, C.M.; Lin, F.G.; Hsu, C.-H.; Kan, P.-C.; Lin, S.-C.; Yang, T.; Chou, Y.-C. DNA Methylation Combinations in Adjacent Normal Colon Tissue Predict Cancer Recurrence: Evidence from a Clinical Cohort Study. *PLoS ONE* 2015, 10, e0123396. [CrossRef]

203. Cha, Y.; Kim, S.Y.; Yeo, H.Y.; Baek, J.Y.; Choi, M.K.; Jung, K.-H.; Dong, S.M.; Chang, H.J. Association of CHFR promoter methylation with treatment outcomes of Imatinib-Based Chemotherapy in Metastatic Colorectal Cancer. *Neoplasia* 2018, 21, 146–155. [CrossRef] [PubMed]

204. Robertson, K.D.; Jones, P.A. DNA methylation: Past, present and future directions. *Epigenetic Diagn. Ther.* 2009, 37–48. [CrossRef]

205. Cha, Y.; Kim, S.Y.; Yeo, H.Y.; Baek, J.Y.; Choi, M.K.; Jung, K.-H.; Dong, S.M.; Chang, H.J. Association of CHFR promoter methylation with treatment outcomes of Imatinib-Based Chemotherapy in Metastatic Colorectal Cancer. *Neoplasia* 2018, 21, 146–155. [CrossRef] [PubMed]

206. Kaminskas, E.; Farrell, A.; Wang, Y.-C.; Sridhara, R.; Pazdur, R. FDA Drug Approval Summary: Azacitidine (5-azacytidine, VidazaTM) for Injectable Suspension. *Oncologist* 2005, 10, 176–182. [CrossRef]

207. Glover, A.B.; Leyland-Jones, B.R.; Chun, H.G.; Davies, B.; Hoth, D.F. Azacitidine: 10 years later. *Cancer Treat. Rep.* 1987, 71, 737–746. [PubMed]

208. Stresemann, C.; Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. *Int. J. Cancer* 2008, 123, 8–13. [CrossRef]

209. Momparler, R.L.; Momparler, L.F.; Samson, J. Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. *Leuk. Res.* 1984, 8, 1043–1049. [CrossRef]

210. Qin, T.; Jelinek, J.; Si, J.; Shu, J.; Issa, J.P. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. *Blood* 2009, 113, 659–667. [CrossRef]

211. Issa, J.P.; Gharibyan, V.; Cortes, J.; Jelinek, J.; Morris, G.; Verstovsek, S.; Talpaz, M.; Garcia-Manero, G.; Kantarjian, H.M. Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. *J. Clin. Oncol.* 2005, 23, 3948–3956. [CrossRef] [PubMed]

212. Juttermann, R.; Li, E.; Jaenisch, R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. *Proc. Natl. Acad. Sci. USA* 1994, 91, 11797–11801. [CrossRef] [PubMed]

213. Derissen, E.J.; Beijnen, J.H.; Schellens, J.H.M. Concise Drug Review: Azacitidine and Decitabine. *Oncologist* 2013, 18, 619–624. [CrossRef] [PubMed]

214. Daher-Reyes, G.S.; Merchán, B.M.; Yee, K.W.L. Guadecitabine (SGI-110): An investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. *Expert Opin. Investig. Drugs* 2019, 28, 835–849. [CrossRef] [PubMed]

215. Chuang, J.C.; Warner, S.L.; Vollmer, D.; Vankayalapati, H.; Redkar, S.; Bearss, D.; Qiu, X.; Yoo, C.B.; Jones, P.A. S10, a 5-Aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. *Mol. Cancer Ther.* 2010, 9, 1443–1450. [CrossRef] [PubMed]
216. Newlands, E.; Stevens, M.; Wedge, S.; Wheelhouse, R.T.; Brock, C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997, 23, 35–61. [CrossRef]

217. Villano, J.L.; Seery, T.E.; Bressler, L.R. Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother. Pharmacol. 2009, 64, 647–655. [CrossRef]

218. Cohen, M.H.; Johnson, J.R.; Pazdur, R. Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme. Clin. Cancer Res. 2005, 11, 6767–6771. [CrossRef]

219. Yamashita, K.; Dai, T.; Dai, Y.; Yamamoto, F.; Perucho, M. Genetics supersedes epigenetics in colon cancer. [CrossRef]

220. Tse, J.W.; Jenkins, L.J.; Chionh, F.; Mariadason, J.M. Aberrant DNA Methylation in Colorectal Cancer: What Should We Target? Trends Cancer 2017, 3, 698–712. [CrossRef]

221. Jansen, Y.J.L.; Verset, G.; Schats, K.; Van Dam, P.-J.; Seremet, T.; Kockx, M.; Van Laethem, J.-L.B.; Neyns, B. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003, 4, 121–131. [CrossRef]

222. Fink, D.; Aebi, S.; Howell, S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 1998, 4, 1–6.

223. Li, H.; Chiappinelli, K.B.; Guzzetta, A.A.; Easwaran, H.; Yen, R.-W.C.; Vatapalli, R.; Topper, M.J.; Luo, J.; Connolly, R.M.; Azad, N.S.; et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5, 587–598. [CrossRef]

224. Kuang, C.; Park, Y.; Bahary, N.; Sun, W.; Ohr, J.; Rhee, J.C.; Marks, S.M.; Beasley, H.S.; Shu, R.; Lin, Y.; et al. Biomarker analysis for UPCI 14–118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 2020, 38, 173. [CrossRef]

225. Jansen, Y.J.L.; Verset, G.; Schats, K.; Van Dam, P.-J.; Seremet, T.; Kockx, M.; Van Laethem, J.-L.B.; Neyns, B. Phase I clinical trial of decitabine (5-aza-2′-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. ESMO Open 2019, 4, e000464. [CrossRef] [PubMed]

226. Garrido-Laguna, I.; McGregor, K.A.; Wade, M.; Weis, J.; Gilcrease, W.; Burt, L.; Soldi, R.; Jakubowski, L.; Davidson, C.; Morrell, G.; et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investig. New Drugs 2013, 31, 1257–1264. [CrossRef] [PubMed]

227. Sharma, A.; Vatapalli, R.; Abdelfatah, E.; McMahon, K.W.; Kerner, Z.; Guzzetta, A.A.; Singh, J.; Zahnnow, C.; Baylin, S.B.; Yerram, S.; et al. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS ONE 2017, 12, e0176139. [CrossRef]

228. Pishvaian, M.J.; Slack, R.S.; Jiang, W.; He, A.R.; Hwang, J.J.; Hankin, A.; Dorsch-Vogel, K.; Kukadiya, D.; Weiner, L.M.; Marshall, J.L.; et al. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer 2018, 124, 2337–2346. [CrossRef]

229. Morano, F.; Corallo, S.; Nigen, M.; Barault, L.; Milione, M.; Berenato, R.; Moretto, R.; Randon, G.; Antista, M.; Belfiore, A.; et al. Temozolomide and irinotecan (TEMRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann. Oncol. 2018, 29, 1800–1806. [CrossRef]

230. Pietrantonio, F.; Lobefaro, R.; Antista, M.; Lonardi, S.; Raimondi, A.; Morano, F.; Mosconi, S.; Rimassa, L.; Murgioni, S.; Sartore-Bianchi, A.; et al. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, advanced colorectal cancer patients bearing MGMT methylation. Clin. Cancer Res. 2019, 26, 1017–1024. [CrossRef]

231. Hochhauser, D.; Glynne-Jones, R.; Potter, V.; Pathiraja, K.; Zhang, Q.; Zhang, L.; Sausville, E.A.; Grávalos, C.; Doyle, T.J. A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promotor. Mol. Cancer Ther. 2013, 12, 809–818. [CrossRef]

232. Stunnenberg, H.G.; Abrignani, S.; Adams, D.; de Almeida, M.; Altucci, L.; Amin, V.; Amit, I.; Antonarakis, S.E.; Aparicio, S.; Arima, T.; et al. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell 2016, 167, 1145–1149. [CrossRef]

233. Abbott, A. Project set to map marks on genome. Nature 2010, 463, 596–597. [CrossRef]